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ABSTRACT

Infectious diseases are the second leading cause of deaths in the world with malaria being
responsible for approximately the same amount of deaths as cancer in 2012. Despite the success
in malaria prevention and control measures decreasing the disease mortality rate by 45% since
2000, the development of single-dose therapeutics with radical cure potential is required to
completely eradicate this deadly disease. Targeting multiple stages of the malaria parasite is
becoming a primary requirement for new candidates in antimalarial drug discovery and
development. Recently, 4(1H)-pyridone, 4(1H)-quinolone, 1,2,3,4-tetrahydroacridone, and
phenoxyethoxy-4(1H)-quinolone chemotypes have been shown to be antimalarials with blood
stage activity, liver stage activity, and transmission blocking activity. Advancements in structureactivity relationship and structure-property relationship studies, biological evaluation in vitro and
in vivo, as well as pharmacokinetics of the 4(1H)-pyridone and 4(1H)-quinolone chemotypes is
discussed in the first chapter of the dissertation.
Convenient synthetic approaches to 3-aryl-4(1H)-quinolones via metal-catalyzed and
metal-free arylation of β-keto carbonyl compounds is addressed in Chapter 2. A clean arylation
protocol of ethyl acetoacetate was developed by using hypervalent diaryl iodonium salts under
mild and metal-free conditions. The scope of the reaction, using symmetric and unsymmetric
iodonium salts varying in sterics and electronics was examined. This method has been applied
for the synthesis of antimalarial compound ELQ-300, which is currently in preclinical
development. Additionally, a first gram scale synthesis of ELQ-300 and its structurally related
vi

4(1H)-quinolone P4Q-391 using operationally simple and highly yielding metal-catalyzed
conditions have been shown.
Despite of 3-aryl-4(1H)-quinolone chemotypes displaying potent antimalarial activities
against Plasmodium species in vitro and in vivo, their development is also associated with risks.
4(1H)-quinolones are known to be poorly soluble and thus represent challenging drug candidates
for pharmacokinetic and bioavailability reasons. Disrupting of molecular crystal packing and
prodrug approaches were employed to overcome solubility and bioavailability issues in current
series. Quantum mechanics torsion profile calculations,
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C T1 spin-lattice relaxation

experiments as well as X-ray studies were conducted with the objective to determine possible
effects improving key physicochemical properties such as solubility and stability.
As a backup strategy, a prodrug approach was developed enabling the 4(1H)-quinolone
scaffold to be functionalized at the quinolone’s oxygen. In order to avoid any enzymatic
dependences, an approach was developed in which the prodrug moiety was removed via a pHtriggered decay. Additionally, phosphate prodrugs regenerating the active compound via
extrahepatic enzymes such as the ubiquitous alkaline phosphatase were investigated. The
development of orally bioavailable prodrugs enabled an advance overcoming in vivo efficacy
limitations and has been confirmed by pharmacokinetic profiling studies. The herein presented
approaches present viable options for any pyridone quinolone antimalarial chemotype which are
currently studied.

vii

CHAPTER ONE: 4(1H)-PYRIDONE AND 4(1H)-QUINOLONE DERIVATIVES AS
ANTIMALARIALS WITH ERYTHROCYTIC, EXOERYTHROCYTIC, AND
TRANSMISSION BLOCKING ACTIVITIES1

1.1 Overview
1.1.1 Main biologically active derivatives
Malaria continues its devastating impact on the health of human populations in tropical
regions, with 207 million cases and approximately 0.7 million deaths in 2012.1 Half of the
world’s population is at risk for malaria with the majority of deaths occurring on the African
continent. Resistance to all known antimalarials and the limited availability of a large number of
efficacious chemotypes are accountable for the wide spread of the disease. Even artemisinin and
artemisinin combination therapies (ACT), currently considered the standard treatments, are
showing signs of emerging resistance.2-5
Over the last decade the number of deaths has decreased by approximately three times
due to renewed efforts to control and kill mosquito populations, as well as improved accessibility
to effective medicines.6 However, to eliminate and eradicate malaria, the discovery of novel
therapeutics which have potential to be used as single-dose agent targeting P. falciparum and as
a radical cure of P. vivax malaria is required. Ideally, such a candidate possesses potent efficacy
against the blood stages of multidrug resistant malaria, blocks transmission of infectious
gametocytes to mosquitoes, and eradicates the liver stages infections, in particular the dormant
1

The entire work presented in this chapter has been accepted with minor revisions for publication in Curr. Top.
Med. Chem. 2014
1

forms (hypnozoites) of the relapsing malaria species (P. vivax and P. ovale). In the past,
antimalarial drug discovery focused primarily on the erythrocytic stages of malaria, however in
recent years, targeting the hypnozoites as well as the infective stages for mosquitoes has been
considered to be equally important.
For a long period of time, 8-aminoquinolines such as primaquine were the only known
antimalarials demonstrating liver stage activity, weak erythrocytic stage activity and
transmission

blocking

activity

simultaneously (Figure 1.1).7 However,
toxicity

in

glucose-6-phosphate

dehydrogenase deficient patients after
administration of primaquine limits its
use.8,

9

Therefore, malaria elimination

efforts continue to focus on the
development of a compound that is safe
and effective at killing malaria parasites
at

all

stages

of

development.

Figure 1.1: Structures of (R,S)-primaquine, atovaquone, as
well as 4(1H)-quinolone and 4-pyridone-based chemotypes
with antimalarial activity

Fortunately, the investment into global antimalarial research over the last decade was expanded
by non-profit organizations such as the Bill and Melinda Gates Foundation (USA), the Medicines
for Malaria Venture (MMV, Switzerland), as well as by other for-profit organizations. In
particular, the increased participation of academic drug discovery units in public-private
partnerships with non-profit and pharmaceutical partners led to about 10 new antimalarial
candidates in the early clinical phased of drug development.10 Unfortunately, only a few of these
are capable of targeting multiple stages of the malaria parasite life cycle. One of these promising

2

preclinical candidates targeting multiple stages of the malaria parasite is ELQ-300, which is
structurally related to the 4(1H)-quinolones and the 4(1H)-pyridones.11
Historically, 3-alkyl- and 3-phenyl-substituted 4(1H)-quinolones (P4Qs) and 1,2,3,4tetrahydroacridones (THAs) were reported to possess causal prophylactic activity (kill growing
exoerythrocytic stage parasites) and potent erythrocytic stage inhibition in avian malaria models,
but not against malaria parasites in mammals.12-14 Similarly, compound ICI56,780, a
phenoxyethoxy-substituted quinolone ester (PEQ) produced a radical cure (eradication of
dormant exoerythrocytic stage parasites known as hypnozoites) in P. cynomolgi infected rhesus
monkeys.15,

16

Finally, the 4(1H)-pyridone clopidol (Figure 1.3) was an in vivo efficacious

antimalarial against blood stages and it was also considered to be curative against the
exoerythrocytic stages (P. gallinaceum and P. cynomolgi) provided it was administered at high
doses over a period of seven consecutive days.17 As these studies were conducted over 20-30
years ago without an adequate evaluation in current preclinical efficacy models and without
assessing physicochemical properties of the compounds, a large number of research groups
recently revisited the development of these chemotypes as antimalarials targeting multiple stages
of the parasite.18-24 Herein, we will discuss these 4(1H)-pyridone and 4(1H)-quinolone
chemotypes, which have potential to be unique antimalarials with blood stage activity,
exoerythrocytic stage activity and transmission blocking activity.
The 4(1H)-pyridone and 4(1H)-quinolone pharmacophores possess a common structural
moiety, which is probably also responsible for their unique antimalarial activity. It has been
shown that the majority of these chemotype analogues are inhibitors of the plasmodial electron
transport chain targeting the parasite’s bc1 complex.11 Remarkably to this date, atovaquone
(Figure 1.1) is the only clinically relevant antimalarial drug inhibiting the same target.25

3

1.1.2 Physicochemical properties of 4(1H)-pyridones and 4(1H)-quinolones
Pyridones are the carbonyl tautomeric forms of hydroxypyridines containing one oxygen
at either the 2-, 3- or 4-position, while quinolones, often also called quinolinones, are pyridones
to which an aromatic ring has been fused
(Figure 1.2). Structural studies of 4(1H)pyridones using X-ray crystallography, IR and
Figure 1.2: Tautomer forms of 4(1H)-pyridones
and 4(1H)-quinolones

liquid NMR suggest that the keto-form is
favored in both solid and liquid states.26, 27 Ion

binding, self-association, and strong solvent effects are responsible for the domination of the
keto tautomer in the liquid state, in the solid state and in solutions. In particular, a crystal
structure of 4(1H)-quinolone exists as a dimer linked by intermolecular hydrogen bonding
(NH1..O4 distance 1.795 Å while the carbon oxygen bond length of 1.246 Å is in the range of a
C=O double bond. At the same time, the presence of a carbon C4 chemical shift at 176.8 ppm in
13

C NMR as well as the splitting of the C2 proton to a triplet in 1H NMR in DMSO indicate the

carbonyl nature of the 4(1H)-quinolone.28 Both 1H NMR and

13

C NMR data also confirm that

4(1H)-pyridones and 4(1H)-quinolones also exist as π-electron delocalized systems with
aromatic character. 4(1H)-pyridones 1.1 are aromatic as long as the lone pair of the nitrogen
electrons can be delocalized into the ring. However, the degree of the aromaticity depends on the
contribution of the pyridinium 1.2 to the overall structure. 4(1H)-Pyridones act like classical
aromatic compounds with electrophilic aromatic substitution (halogenation, nitration, etc.)
occurring selectively at position C3, while the C4 carbonyl undergoes nucleophilic substitution
by halogens when reacting with POCl3 or PCl5. Finally, the powder FT-IR of 4(1H)-quinolones
displays only a stretching of the C=O bond at 1505 cm-1 without a hydroxyl peak.28 Despite the
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predominance of the keto-form in solid and liquid states, structural studies of gas phase
pyridones reveal an enol character which strongly suggests the existence of a tautomeric
equilibrium.27
1.1.3 Synthesis of 4(1H)-pyridones and 4(1H)-quinolones
The synthesis of 4(1H)-pyridones proceeds by a cyclocondensation of 1,3,5-tricarbonyl
compounds with ammonia.29 The formation of asymmetrical 2,6-substituted 4(1H)-pyridones is
possible via a cyclocondensation of dianions of β-dicarbonyl compounds with nitriles, although
the best results are obtained by the procedure described by Letsinger through pyrone
intermediates.30 Finally, 4(1H)-pyridones are also accessed via [5+1] hererocyclization of 2azadienes with 1,1-carbonyldiimidazole.31 At the same time, synthesis of 4(1H)-quinolones is
traditionally accomplished via Conrad-Limpach,32 Niementowski,33 Gould-Jacobs34 or Camps35
cyclizations. Among common disadvantages of these transformations are elevated reaction
temperatures, low reproducibility and poor-to-moderate reaction yields. Recently, several novel
synthetic approaches involving transition metal catalysis with improved yields and
regioselectivity has been reported.36-38

1.2 Atovaquone and Other Naphthoquinones
Plasmodium cytochrome bc1 complex is a validated antimalarial target with atovaquone
(Figure 1.1) being the only drug targeting bc1, which is currently in clinical use. The
mitochondria play a pivotal role in the parasite life cycle and as a part of the energy household,
bc1 complex is actively involved in the electron transport chain. Fortunately, structural
differences between the organelle’s components of the human cell and parasite’s one impelled
the development of selective inhibitors targeting the Plasmodium bc1 complex. There are two
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specific ubiquinone binding sites (ubiquinol oxidation site Q0 and the ubiquinone binding site Qi)
within the bc1 complex and studies have shown that atovaquone competitively inhibits the Q0
site.25
Atovaquone belongs to the class of naphthoquinone and it was discovered in the early
1990s. Shortage of quinine during World War II led to the development of new antimalarial
programs with a variety of chemotypes being tested in a bird assays. Opportunely,
naphthoquinone compounds had emerged as an attractive class of antimalarials with suppressive
in vivo activities against P. lophurae in ducks.39 SAR studies of more than three hundred
naphthoquinones resulted in few 2-alkyl substituted compounds, which in 1943 were also tested
in clinical trials. Unfortunately, the best results of the series showed only temporary suppression
of fever extending for an of average of 10 days in eight cases.40 The clue to 2-alkyl
naphthoquinones inactivity in human was revealed in the same report with poor PK parameters
being the reasons for the failure.
Development of a reliable and adequate in vitro assay against P. falciparum allowed
researchers at Welcome Research Laboratories to revisit the naphthoquinone chemotype in
1980s.41 Low metabolic stability was identified as the main reason for the poor performance in
the efficacy models and main efforts were directed on improvement of the abovementioned
property. A variety of 3-cycloalkyl-2-hydroxy naphthoquinones was tested in vitro with some of
them showing excellent subnanomalor activities. However, only one compound, atovaquone,
was relatively stable to human liver microsomes showing promising antimalarial efficacy in
vivo.42 The clinical studies involving 1,395 patients were conducted between 1990 and 1996 and
evaluated atovaquone alone or in combination with other drugs for treatment of malaria. The
overall cure rate was more than 98% in about 500 patients infected with P. falciparum.43
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Atovaquone is used since then as a fixed-dose combination therapy with dihydrofolate reductase
inhibitor proguanil (Malarone, GSK).
Unfortunately, mutations within the catalytic domain of the cytochrome bc1 complex led
to emergence of resistance to atovaquone.44 Additionally, resistance appeared to occur primarily
through a single point mutation in position 268 in cytochrome bc1.45 Despite the rapid
development of resistance to atovaquone, the cross-resistance between this quinone and other
antimalarials has not been observed.43 These results suggested the uniqueness of atovaquone’s
mechanism of action in comparison to other marketed antimalarials. Although a series of
mutations is required to achieve complete resistance to proguanil, the evolution of drug-resistant
strains of P. falciparum to Malarone is a developing threat and could pose an increasingly
serious problem to public health worldwide.46 Antimalarial activity against atovaquone-resistant
strains is mandatory requirements in preclinical development of novel bc1 inhibitors.
Notwithstanding growing parasite resistance to atovaquone, the compound shows
antimalarial activity against liver, blood and asexual stages of Plasmodium life cycle. In order to
eliminate malaria, compounds are required which not only target blood stages of the disease but
also the liver stages as well as the infectious stages for mosquitoes. Ultimately, the centrality of
malarial bc1 complex makes it an attractive target for the development of antimalarials with
blood, liver and transmission blocking activity.

1.3 (1H)-Pyridones
1.3.1 Historical overview
The antimalarial activities of clopidol 1.3, 3,5-dichloro-2,6-dimethyl-4(1H)-pyridone
(Figure 1.3), were described by the Walter Reed Army Institute of Research (WRAIR) in the late
1960s.17 In a concise article, clopidol was reported to have in vivo activity against P. falciparum
7

(chloroquine resistant), P. berghei, P. cynomolgi and P. gallinaceum. Unfortunately, clinical
trials in humans at that time failed most likely because of pharmacokinetic issues (high clearance
and low solubility) and simple
acylations or sulfonations did not
yield clopidol derivatives with
improved

physicochemical

properties.17 Early investigations
on the mechanism of action of
clopidol
Figure 1.3: Chemical structures of clopidol, GW844520,
GSK932121 and its phosphate prodrug

indicated

that

the

mitochondria electron chain was

inhibited.47 This outcome was later confirmed by the Burroughs Welcome (BW) Laboratories.48
Importantly, compound 1.3 maintained potent antimalarial activity against atovaquone resistant
strains of malaria suggesting a different site of action for 1.3 than the ubiquinol oxidation site Qo
of the bc1 complex for atovaquone.48
1.3.2 Structure-activity relationship (SAR) studies of 4(1H)-pyridones
A few decades later, these results motivated scientists at GSK to renew lead optimization
studies of a pyridine lead identified during the atovaquone development at BW. The C2, C3, C5,
and C6 positions of 1.3 were optimized in a detailed structure-activity relationship study on the
4(1H)-pyridone scaffold.18 First, the halogenation of the C3 position significantly improved the
activity in vitro and in vivo over unsubstituted analogues. However, no significant differences
between the 3-Br or the 3-Cl analogues were observed (EC50 (3-Cl) = 0.005 µM, EC50 (3-Br) =
0.008 µM, and EC50 (3-H) = 0.16 µM). Relative to the 3-halo-4(1H)-pyridones, other electron
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withdrawing groups (3-NO2 or 3-CF3) did not display any improvements, while compounds with
an electron donating substituent (3-OCH3) lost all antimalarial activity.
For the C2 and C6 positions, a substantial loss in activity was observed when the 2-CH3
and 6-CH3 (EC50 3D7A = 0.2 µM) groups were replaced by CF3 groups (EC50 (3D7A) > 1 µM).
This observation is in alignment with a previous report, in which electron-withdrawing groups
(2-CF3) have been shown to shift the tautomeric equilibrium towards the enol isomer.26 These
results strongly suggest the importance of the keto-tautomer to maintaining antimalarial
activities.

Figure 1.4: Optimization of clopidol leading to 4(1H)-pyridones with improved in vitro and in vivo antimalarial
activity. Note that the residues are ordered according to decreasing in vitro antimalarial activity against the T9-96
strain of P. falciparum

Finally, substitution at the C5 position proved to play the most important role in terms of
efficacy as well as physicochemical properties. Initial improvements of clopidol were achieved
by changing one of the chloro substituents to an alkyl chain, a phenyl, the atovaquone-like side
chain 4-(4-chlorophenyl)cyclohexyl, or a diaryl ether moiety (Figure 1.4).18 Introduction of a
phenyl group at the C5 position modestly improved the in vitro activity against T9-96, a
chloroquine sensitive strain of P. falciparum, by a factor of two over 1.3, while the installation of
an n-octyl chain at C5 further enhanced the potency yielding an EC50 of 4 µM. Nevertheless,
9

both compounds lost their in vivo activity in a 4-day suppressive mouse P. yoelii assay (ED50 =
20 mg/kg and ED50 > 60 mg/kg respectively) presumably due to metabolic issues. The use of a
diaryl group mimicking the side chain of atovaquone dramatically decreased the EC50 value to
0.4 µM, while the in vivo activity improved from an ED50 value of 40 mg/kg for 1.3 to an ED50
value of 0.6 mg/kg for the 5-diaryl-substituted 4(1H)-pyridone. Additional optimization of the
distal aromatic ring and introduction of an oxygen as a spacer between the two aromatic rings of
the 5-diaryl moiety provided compound 1.4 with promisingly low nanomolar in vitro activity and
excellent in vivo activity with an ED50 value of 0.2 mg/kg in the murine P. yoelii model. This
optimization leading to GW844520 corresponds to an approximate 200-fold improvement in
potency over the starting point clopidol.18
In addition to excellent activity against erythrocytic stages of P. falciparum parasites, 1.4
also showed remarkable activity towards liver stages of P. falciparum (EC50 = 48.8 µM) and
blood stages of P. vivax (EC50 < 4.88 µM), while no cytotoxicity against human cell lines was
observed (EC50 > 6.1 mM). Furthermore, a selectivity index was confirmed in inhibition studies,
in which 1.4 was shown to selectively inhibit plasmodial cytochrome bc1 complex over
mammalian cytochrome bc1. The IC50 for plasmodial cytochrome bc1 complex III (IC50 = 0.002
µM) was shown to be approximately 250-fold lower than the corresponding human protein (IC50
= 0.51 µM).49 The inhibition of P. falciparum complex II and complex IV was weak (IC50 > 3
µM).
Compound 1.4 was also tested against multidrug resistant strains (3D7A, FCR3, K1,
Dd2, Hb3 and W2) of P. falciparum and showed no cross-resistance with any of the tested
strains including the atovaquone resistant strain FCR3, suggesting a slightly different binding
mode to cytochrome bc1 despite its similar mechanism of action.49 Importantly, the FCR3
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atovaquone resistant strain does not possess the clinically relevant amino acid 268 mutation in
cytochrome b.
1.3.3 Preclinical studies of 4(1H)-pyridones
Based on the promising antimalarial profile, compound 1.4 entered preclinical trials in
2006;50 however, it was discontinued because of histopatological complication in skeletal and
cardiac muscles. These results were probably caused by the high lipophilicity (logD pH7.4 =
2.79) and the long half-life (t1/2 = 143 h in a dog) of 1.4. Consequently, oral bioavailability of
lead GW844520 was also extremely low at higher dosage (% F = 4 at a 2mg/kg dose in dogs and
% F = 20 at a 10mg/kg dose in mice) mainly because of poor aqueous solubility (pH 2-12 < 0.1
µg/ml).51 The lack of dose linearity of 1.4 in the preclinical studies triggered the initiation of a
back-up program at GSK with the goal to design 4(1H)-pyridones with higher solubilities and
increased bioavailabilities.52 Introduction of a hydroxymethyl moiety at C6 yielded compound
GSK932121 (1.5) (Figure 1.3), whose solubility at lower pHs (simulated gastric fluid (SGF) pH
1.2 = 372 mg/ml, fed state simulated intestinal fluid (FeSSIF) pH 5.0 = 2.34 mg/ml) was
significantly increased in comparison to its solubility at pH 7.4 (PBS pH 7.4 < 0.1 mg/ml). As
such, the oral bioavailability of 1.5 was improved to 16 % in a dog model at 2 mg/kg doses.
Importantly, incorporation of the hydroxymethyl group at C6 retained the in vitro (EC50 3D7A =
0.002 µM) and in vivo efficacy (ED50 = 0.3 mg/kg in the murine P. yoelii model). The
formulation approach was used to enhance the oral bioavailability and allowed 1.5 to progress to
first-time-in-human (FTIH) studies. Despite promising early results, these studies were
terminated due to unexpected acute toxicity with the water-soluble phosphate prodrug 1.6
(Figure 1.3) in rats. Prodrug approach with compound 1.6 progressed into preclinical trials in
parallel with FTIH study as a back-up. The toxicity was attributed to the inhibition of
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mammalian bc1 cells by parent compound 1.5. Despite the difficulties associated with the
toxicity of GSK compounds in humans, 4(1H)-pyridones remain an attractive chemotype with
potential to be efficacious not only against the blood forms of parasite, but also against other
stages such as liver and mosquito forms acting as prophylactic and transmission blocking agent.

1.4 4(1H)-Quinolones
1.4.1 Historical overview
Before the beginning of World War II, German chemists from Bayer discovered
prophylactic antimalarial activity with endochin (1.7), a 3heptyl-7-methoxy-2-methyl-4(1H)-quinolone (Figure 1.5).53
The prefix “endo-“ was chosen as this new antimalarial
appeared to inhibit sporozoites and infected endothelial cells

Figure 1.5: Chemical structure of
endochin

of liver stages, while the suffix “-chin” was common to many antimalarials related or unrelated
to the alkaloid quinine (German: chinin).54 It was not until the end of the war when the first
results on the antiplasmodial activity of 1.7 were published.14 Remarkably, endochin showed
activity in an avian malaria model against all three stages of the parasite life cycle: host liver,
blood, and mosquito stages.54 Despite demonstrated efficacy of endochin towards P. gallinaceum
in chicken and P. praecox in canaries, initial trials in humans failed12, likely because of
unfavorable pharmacokinetics. When better in vivo malaria models became available, 1.7 was
tested by Walter Reed Army Institute of Research in 1974 in the gold standard P. cynomolgi
infected Rhesus radical cure assay and found to be inactive.55
Around the same time, Casey at the University of Bridgeport prepared 15 endochin
analogues focusing on 3-alkenyl- and 3-alkyl-substituted 2-methyl-4(1H)-quinolones.12 Only two
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of the tested compounds showed antimalarial activity in P. gallinaceum and P. berghei assays.
The 4(1H)-quinolone with an (E)-(dodec-1-en-1-yl) side chain at the C3 position cured two out
of five mice at a dose of 640 mg/kg in the Rane single dose malaria model.12 The N-oxide of
endochin was the second compound displaying in vivo activity in the same malaria model
confirming the initial assumption that the poor bioavailability of endochin limited its use in
mammals. It is also noteworthy that in 1968 Lemke and co-workers reported a series of 3unsubstituted 4(1H)-quinolone-2-carboxylates which were inactive against P.berghei in a murine
model.56
1.4.2 SAR studies of 4(1H)-quinolones: 3-alkyl derivatives
4(1H)-quinolones regained attention by several research teams at the beginning of this
century. First, Kyle and co-workers at the Walter Reed Army Institute of Research reevaluated
approximately 30 structurally related 4(1H)-quinolones for in vitro erythrocytic activity against
D6 (chloroquine and atovaquone susceptible) and TM90-C2B (chloroquine, mefloquine, and
atovaquone resistant) strains of P. falciparum.57 Notably, several 4(1H)-quinolones demonstrated
exceptional in vitro activity with potencies in the low nanomolar ranges while the crossresistance with atovaquone was not complete across the 4(1H)-quinolone series.57 Moreover, the
efficacy of WR193211 (3-geranyl-substituted 2-methyl-4(1H)-quinolone, one of Casey’s
compound) was reevaluated and proven to display modest in vivo activity in a modified
Thompson Test with P. berghei (compound given daily for three days) with an ED90 of 97
mg/kg. Subsequently in 2007, Riscoe and Winter reported similar results with endochin and 8
analogues thereof.21
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1.4.3 SAR studies of 4(1H)-quinolones: optimization of the C5-C8 benzenoid ring
For the optimization of endochin, Manetsch and Kyle combined an extensive structureactivity relationship study with a structure-property study as endochin appeared to be limited by
its physicochemical properties.19 While the n-alkyl chain at the C3 position was identified to play
an important role for the antimalarial activity, it was also found to be a major liability in terms of

Figure 1.6: Structure-activity relationship (SAR) studies for the optimization of endochin

aqueous solubility and microsomal stability (Figure 1.6). Nevertheless, initial optimization
efforts focusing primarily on antimalarial activity yielded 3-alkenyl-substituted 4(1H)quinolones which were approximately 2-fold more potent in comparison to 3-alkyl-4(1H)quinolones. In contrast, 3-alkynyl-substituted compounds or 4(1H)-quinolones unsubstituted at
the C3 position completely lacked in antimalarial activity. Modest results were obtained with 3aryl-substituted 4(1H)-quinolones displaying EC50s in the submicromolar range.
A systematic approach following the Topliss operational scheme for aromatic
substituents was applied to probe the benzenoid ring for steric and electronic effects. The C5, C6,
C7, and C8 positions of 3-phenyl- or 3-benzyl-2-methyl-4(1H)-quinolones were altered with a
methoxy-, a chloro-, or a dichloro-substitution. Best potencies were observed with compounds
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substituted at the benzenoid ring with a chloro group at the C6 or with a methoxy group at the C7
position. Combination of a 6-chloro and a 7-methoxy group within the same 4(1H)-quinolone
greatly synergized the substituent effects and improved the in vitro potency up to 20-fold. In
addition, the 6-chloro-7-methoxy substitution combination gave rise to an array of 4(1H)quinolones displaying equal antimalarial potency against the TM90-C2B (atovaquone resistant)
and the W2 (chloroquine resistant) strains of P. falciparum which consequently lowered the
atovaquone cross-resistance index (RI: EC50 ratio of TM90-C2B to W2) to an optimal value
close to 1. Atovaquone resistance of TM90-C2B is caused by a specific mutation altering the
wild type from Tyr268 to Ser268 in the parasite’s cytochrome b gene of cytochrome bc1.58
Compounds with RI = 0.3 – 3.0 are considered acceptable in terms of risk to cross-resistance
with atovaquone, whereas compounds with RI > 10 and RI < 0.1 are likely to have clinically
relevant levels of cross-resistance with atovaquone.43, 59
The authors also attempted to lock a particular 4-quinolone in its tautomeric forms via Nor O-alkylation of the 4-quinolone core. Predominantly, the keto form of a 4(1H)-quinolone is
favored over enol form in both solid and solution states.28 Several N-methylated 3-benzylsubstituted 4-quinolones and their O-methylated analogues have been shown to completely lack
in antimalarial activity in comparison to their corresponding 4(1H)-quinolones (Figure 1.6).
These results suggest that the hydrogen bond donors and hydrogen bond acceptors typical of a
4(1H)-quinolone scaffold are likely required for a tight interaction with the parasite target.
Among the most promising candidates in the initial library of approximately 70 4(1H)quinolones was P4Q-95 (1.8, Figure 1.7) with EC50s comparable to endochin (P4Q-95: EC50
(W2) = 26 nM, EC50 (TM90-C2B) = 15 nM; endochin: EC50 (W2) = 8.6 nM; EC50 (TM90-C2B)
= 47 nM). Importantly, 1.8 also displayed better microsomal stability and slightly better aqueous
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solubility in comparison to endochin. Based on these promising results, 3-phenyl substituted
P4Q-95 was assessed in vivo in mice (Thompson test, P. berghei), but unfortunately 8 lacked in
in vivo antimalarial activity most likely due to low aqueous solubility.60
A first successful in vivo efficacy study with an optimized endochin analogue was
reported by Riscoe and co-workers in 2011.61 For the orally administered prodrug ELQ-125, a
polyethylene glycol carbonate derivative of 3-heptyl-5,7-diflouro-2-methyl-4-quinolone, an ED50
value of 11 mg/kg was obtained against P. yoelii infections in CF1 mice. ELQ-125 emerged
from an optimization study comprising approximately thirty 3-alkyl-substituted 4(1H)quinolones differing primarily at their benzenoid ring substituents. The most potent compounds
had EC50 values in the picomolar range against the chloroquine resistant strain Dd2, although
these compounds were not as potent against the atovaquone resistant strain TM90-C2B. For
example, the resistance index for compound ELQ-125 was approximately 365 (ELQ-125: EC50
(Dd2) = 0.4 nM, EC50 (TM90-C2B) = 146 nM) suggesting strong potential for reduced efficacy
against clinically relevant atovaquone resistant strains of malaria.
1.4.4 SAR studies of 3-aryl-4(1H)-quinolones and advancement of P4Q-391 and ELQ-300 into
preclinical development
The experimental evidence that the orally administered prodrug ELQ-125 displayed good
in vivo efficacy underscored the great promise of endochin derivatives as antimalarials. In
addition to this, the potent in vitro antimalarial activity, the advantageous resistance index, the
moderately improved physicochemical properties, as well as the synthetic tractability of P4Q-95
motivated the various scientists (University of South Florida, Oregon Health and Sciences
University, Drexel University, Monash University, and MMV) to combine efforts in a
multidisciplinary lead optimization program. Concerted optimization efforts led to the discovery
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of 3-diarylethers-4(1H)-quinolones ELQ-271 (1.9), ELQ-300 (1.10) and P4Q-391 (1.11), of
which ELQ-300 was nominated as a preclinical candidate (Figure 1.7).11 The C3 substituent of
ELQ-271 and ELQ-300 correspond exactly to the side chain of GSK’s analogue GW8444520,
while the 6-chloro-7-methoxy benzenoid substituent in ELQ-300 and P4Q-391 is identical to the
benzenoid substitution pattern of 4(1H)-quinolone P4Q-95 (Figure 1.7). The combination of
these substitutions at C3 improved physiochemical properties whilst 6-chloro-7-methoxy proved
critical for remarkable selectivity for parasite versus mammalian cytochrome b.
ELQ-300 was potent in the in vitro erythrocytic assay against a chloroquine-sensitive
strain (EC50 (Dd6) = 2.2 nM) and multidrug-resistant strains of P. falciparum (EC50 (W2) = 1.8
nM) including the atovaquone-resistant clinical clones (EC50 (TM90-C2B) = 1.7 nM).
Furthermore, both ELQ-300 and P4Q-391 showed excellent in vivo efficacy against the blood
stages (Thompson Test, P.
berghei: ELQ-300 ED50 =
0.016

mg/kg;

P4Q-391

ED50 = 0.27 mg/kg) and
the liver stages (P. berghei
sporozoite
Figure 1.7: Chemical structures of 3-aryl-4(1H)-quinolones P4Q-95, ELQ271, P4Q-391, ELQ-300

mice

infection

followed

of
by

bioluminescence imaging:
ELQ-300 blocking dose > 0.03 mg/kg; P4Q-391 blocking dose > 0.1 mg/kg). Moreover, both
compounds were extremely effective in blocking transmission to the mosquito vector.
Gametocytes treated with as low as 0.1 µM of ELQ-300 did not develop past stage III while a
minimum concentration of 1 µM was needed for P4Q-391 to inhibit gametocyte growth past
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stage IV. ELQ-300 and P4Q-391 were also shown to inhibit the formation of zygote, ookinete,
and oocyst forms of the mosquito life cycle. The mechanism of action for both compounds was
also found to be associated to the cytochrome bc1 complex. Fortunately, although the Q0 site of
plasmodial mitochondrial cytochrome bc1 complex is a common target for both drugs, the
selectivity index for ELQ-300 was greatly improved (>18000) for Plasmodium bc1 versus human
bc1 due to the 6-chloro-7-methoxy substitution pattern.
One limitation of ELQ-300 is its poor aqueous solubility (fasted state simulated intestinal
fluid (FaSSIF) pH 6.5 = 0.3 µM) which has direct impact on the pharmacokinetic profile of the
compound.11 The oral bioavailability of ELQ-300 in mice was excellent (~100%) at a dose of 0.3
mg/kg with PEG-400 vehicle in a P. yoelii efficacy model. However, increasing the dose
concentration resulted in a decrease of bioavailability. The absence of dose-proportionality
impedes the determination of the therapeutic index and in vivo toxicity. Alternative approaches
such as prodrugs or formulation are required to overcome this solubility constraint. Nevertheless,
as of today, ELQ-300 remains one of the five preclinical candidates in the MMV pipeline.10
1.4.5 SAR studies of 4(1H)-quinolones: 2-substituted derivatives
O’Neil, Ward and coworkers developed a series of 2-substituted 4(1H)-quinolones with a
dual mechanism of action against two enzymes of the Plasmodium mitochondrial electron
transport

chain:

the

NADH:ubiquinone

oxidoreductase (P. falciparum NDH2) and
cytochrome

bc1.22

Hydroxy-2-dodecyl-

4(1H)-quinolone (HDQ), a known PfNDH2
Figure 1.8: Chemical structures of P. falciparum NDH2
inhibitors

inhibitor was utilized as a starting point for

the selection of approximately 17,000 compounds, which were tested in a high-through-put
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screening against PfNDH2. Follow-up hit-to-lead optimization yielded frontrunner 4(1H)quinolone CK-2-68 (1.13), in which the 2-dodecyl side chain of HDQ was replaced by a bis-aryl
side chain (Figure 1.8).22 Generally, the overall trends of this structure-activity relationship study
(Figure 1.9) closely resemble the trends of the 3-substituted quinolones reported by Manetsch,

Figure 1.9: SAR studies of 2-aryl-4(1H)-quinolones

Kyle and Riscoe (Figure 1.6).
The benzenoid ring of the 4(1H)-quinolone core tolerated substitutions at the C6 and C7
positions, while any modification at C5 or C8 significantly decreased the antiplasmodial
activities (Figure 1.9).22 Secondary in vitro activities of C3 methyl substituted 4Qs versus
unsubstituted analogs are overtaken by better physiochemical properties of the formers due to
increased rotational barrier along quinolone-aryl σ bond. More importantly, the nature of the C2
and C3 substituents determined the selectivity of this 4(1H)-quinolone series with 2-diaryl
substituted compounds being selective towards PfNDH2, while 3-substituted analogues
preferentially target the parasite’s cytochrome bc1 complex. Compound 1.13 has good activity
against the blood with an EC50 value of 36 nM against 3D7 and a strong inhibition of PfNDH2
19

(IC50 = 16 nM). The compound also showed 100% suppressive activity in mice infected with P.
berghei (Peter’s 4 day in vivo test) administrated either as a prodrug or in conjunction with a
solubilizing formulation.22 Selective 4(1H)-quinolones including CK-2-68 were also tested
against multidrug resistant strains of P. falciparum and while the in vitro activity against the
chloroquine resistant clone W2 were similar to 3D7 (resistance index of approximately 1),
compounds were not equipotent towards the atovaquone resistant strain TM90-C2B (EC50 = 178
nM).
The low aqueous solubility and the necessity of approaches utilizing a prodrug moiety or
formulations led to a design of compounds containing a heterocyclic sidechain.62 In comparison
to 1.13, compound SL-2-25 (1.14, Figure 1.10) conserved the promising antimalarial activity
against the 3D7 strain of P. falciparum (EC50 = 54 nM) and
the target PfNDH2 (IC50 = 14 nM), while an oral
administration showed activity with an ED50 value of 1.9
mg/kg in a P. berghei model of malaria when given as a
Figure 1.10: Chemical structure of
SL-2-25

phosphate salt. At the same time 1.14 is also equipotent
against the parasite bc1 complex (IC50 = 15 nM). However, it

shows reduced activity towards the atovaquone-resistant strain TM90-C2B (EC50 = 156 nM),
yielding a resistance index of approximately 3. Generally, 2-pyridyl-4(1H)-quinolones are
considered to be attractive templates for further lead optimization of 4(1H)-quinolones with dual
mechanisms of action.
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1.5 3-Ester-4(1H)-Quinolones
1.5.1 Historical overview
At Imperial Chemical Industries (ICI), Ryley and Peters reported a study on the
development of an anti-coccidial agent as a potent antimalarial.15 Compound ICI56,780, a 7-(2phenoxyethoxy)-4(1H)-quinolone (PEQ) (1.15, Figure 1.11), was shown to possess causal
prophylactic (single dose of 30 mg/kg subcutaneous) and
blood schizonticidal activity (ED50 = 0.05 mg/kg) in rodent
malaria models. Unfortunately a high degree of resistance to
Figure 1.11: chemical structure of
ICI56,780

1.15 was obtained after one passage in P. berghei infected
mice and the lack of oral bioavailability led to abandonment

of this series of compounds. Approximately twenty years later, Puri and Dutta retested 1.15 and
produced radical cures (eradicate dormant hypnozoites) in P. cynomolgi infected Rhesus
monkeys.16 Antimalarials which have proven in vivo activity at eradicating hypnozoites of P.
cynomolgi have potential to be used as radical cures representing targets of highest priority for
the worldwide malaria eradication initiative.
1.5.2 SAR studies of phenoxyethoxy-substituted quinolone esters (PEQs)
To overcome the resistance issue related to the PEQs, the Kyle and Manetsch laboratories
conducted a structure-activity relationship study on a series of 29 novel PEQs in 2011.23 The
most

promising

compound

of

this

PEQ

series

was

6-butyl-3-(2-fluoro-4-

(trifluoromethyl)phenyl)-7-(2-phenoxyethoxy)-4(1H)-quinolone which was reported to have a
more than 200 fold improvement in RI (EC50 (TM90-C2B) = 31 nM, EC50 (W2) = 28 nM; RI =
1.1) over the parent compound 1.15 (EC50 (TM90-C2B) = 0.05 nM, EC50 (W2) = 11.2 nM; RI =
224). Superior blood stage activity and improved RI values were obtained with the 7-(2-
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phenoxyethoxy) substituted 4(1H)-quinolone, while the presence of the hydrophobic butyl group
at the C6 position was identified to be important in maintaining potent antimalarial activities. In
contrast, the majority of the reported PEQs suffered from poor metabolic stability and limited
aqueous solubility [unpublished data].
Similarly, an antimalarial series of twenty 4(1H)-quinolone esters that were monosubstituted at the C6 or C7 positions with one aryloxy or benzyloxy moiety was reported by
Cowley et al in 2012.63 Each of the compounds was tested only in vitro against the chloroquinesensitive strain 3D7 of P. falciparum. The structure-activity relationship data suggests that a C7
aryloxy or benzyloxy substitent was preferred over the same analogues substituted at C6 by an
approximate factor of 300. Furthermore, the importance of the ester group at C3 was also
established. The most promising quinolone ester from this series was confirmed to be active
against the plasmodial bc1 complex (IC50 = 1.3 nM). Docking studies with the best compound
binding to the Qo site of yeast bc1 complex suggested the existence of strong hydrogen bonding
between the quinolone’s nitrogen and oxygen with the His182 and Glu272 residues.63
1.5.3 SAR studies of 2-aryl-3-ester-4(1H)-quinolones
An extensive work on lead optimization of 2-aryl-3-ester-4(1H)-quinolones was reported
by Guy and co-workers.24 Approximately 100 derivatives of 4(1H)-quinolones were synthesized
and tested against an array of P. falciparum strains (chloroquine and pyrimethamine resistant
strain K1; chloroquine, mefloquine, pyrimethamine, and atovaquone resistant strain TM90-C2B;
chloroquine sensitive strain D10; and DHODH inhibitor resistant strain D10_yDHOD). A
systematic approach including a methodical variation of sterics, electrostatics and hydrophobics
following Topliss and Hansch analysis was applied to conduct the optimization. A metasubstituted aryl group at the C2 position was established to be extremely important for
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antimalarial activity.64 In order to investigate this trend more precisely, more than 20 additional
analogues were synthesized and tested in vitro (Figure 1.12). Hydrophobic and electron-donating

Figure 1.12: SAR studies of 2-aryl-3-ester-4(1H)-quinolones

groups at the meta-position were determined to be the preferred C2 aryl substituents.
Interestingly, a linear correlation between the pEC50 (K1) values and the hydrophobicity (R2 =
0.74) was identified while performing Hansch analysis. In contrast, no correlation between
antimalarial activity and electronic effects were observed, which highlights a direct relationship
between hydrophobicity and potency for these 2-aryl-3-ester-4(1H)-quinolones. For these 4(1H)quinolone esters, it was therefore concluded that during the optimization process the antimalarial
activity and key physicochemical properties needed to be carefully counterbalanced.
Introduction of an electron-donating group at the C7 position of the 4(1H)-quinolone
benzenoid ring greatly improved the antimalarial activity, while an electron-withdrawing group
caused a significant drop in potency (Figure 1.12). At the same time, the addition of a halogen
substituent at the C6 position improved the antimalarial activity primarily against the TM90-C2B
strain and consequently the RI value to approximately 1. Lastly, incorporation of different
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solubilizing moieties at the C3 ester position substantially reduced the potency in comparison to
the ethyl ester 4(1H)-quinolone starting point.
Parallel assessment of the in vitro activity and physicochemical property data led to the
decision to test nine of these 4(1H)-quinolone esters in a Thompson test for in vivo activity. Of
all the tested compounds, only two showed suppressive activities. For instance, ethyl 2-(3chlorophenyl)-6-fluoro-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate

displayed

low

nanomolar EC50s against K1 (EC50 = 80 nM) and TM90-C2B (EC50 = 200 nM) strains of P.
falciparum, but it was highly soluble at pH 7.4 even at concentrations of 20 µM and possessed
good permeability (PAMPA pH 7.4 = 410 cm/s). Not surprisingly, it was efficacious in vivo,
demonstrating a 57% suppression of parasitemia on day 6 postinfection at an oral dose of 30
mg/kg.
Despite the excellent activities in vitro for the best 2-aryl-3-ester-4(1H)-quinolones, they
are approximately 50-fold less potent in vivo in comparison to
the 4(1H)-quinolones such as ELQ-300 or P4Q-391 (Figure 1.7)
developed by the Manetsch and Riscoe groups. These
Figure 1.13: Chemical structure
of decoquinate

compounds also appear to target the plasmodial cytochrome bc1
complex as increased toxicity was observed with repeated

dosing suggesting partial inhibition of mammalian bc1 complex. Nonetheless, 2-aryl-3-ester4(1H)-quinolones possess great potential for future development as there is high potential for
additional bioavailable improvements.
Recent screening of 1037 existing drugs targeted against P. berghei liver stages identified
decoquinate 1.16 as the most potent inhibitor (EC50 = 2.6 nM) (Figure 1.13).65 This result is not
unexpected considering that antimalarial activity of decoquinate against P. berghei was first
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reported by Ryley and Peters in their anti-coccidial study.16 In addition, Puri and Dutta also
showed that compound 1.16 possessed anti-hypnozoite activity in a P. cynomolgi infected
Rhesus model when administrated as the ester prodrug WR 194905. Further investigation of this
quinolone ester confirmed selective inhibition of plasmodial cytochrome bc1 complex.65

1.6 1,2,3,4-Tetrahydroacridones
1.6.1 Historical overview
Antimalarial activity of 1,2,3,4-tetrahydroacridin-9(10H)-ones (THAs) was reported
initially by Stephen and co-workers in 1947.13 More than a dozen THA analogues were tested
using

an

in

vivo

assay

against

P.

gallinaceum infections in chicks with a few
compounds
Figure 1.14: Chemical structures of 1,2,3,4tetrahydroacridin-9(10H)-ones and 3,4-dihydroacridine1,9(2H,10H)-diones

having

minimum

effective

doses as low as 12.5 mg per 100 g (Figure
1.14, compound 1.17). At approximately the

same time, endochin (Figure 1.5) was discovered to have prophylactic antiplasmodial activity,
which surpassed the prophylactic activity of most of the THAs. Because of this, the next 50 years
of optimization efforts focused primarily on 4(1H)-quinolones and 4(1H)-quinolone esters
instead of the THAs. Nevertheless, interesting reports on the antimalarial properties of THAs
were published in the past decades.
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1.6.2 Floxacrine and other dihydroacridinediones
The dihydroacridinediones, which are structurally related to the THAs (Figure 1.14,
compound 1.18), were studied in great detail over the course of last 30 years. Floxacrine (Figure
1.15, compound 1.19), first reported
by

Durckheimer

discovered

to

in
have

1975,

was

promising

antimalarial activity including causal
prophylactic

activity.66

Extensive

Figure 1.15: Chemical structures of floxacrine, WR 243251, and
WR 243246.

optimization of floxacrine was conducted by several research groups with the hope to address the
poor aqueous solubility, atovaquone cross resistance, and the dose-dependent chronic
periarteritis caused by floxacrine.67 Compound WR243251 (1.20), a prodrug of WR243246
(1.21), was developed and shown to generate cures in Aotus monkeys infected with the Smith
strain (chloroquine, quinine, and pyrimethamine resistant) of P. falciparum at a dose of 16
mg/kg. Unfortunately, prodrug 1.20 was abandoned in the late preclinical development stage
because of cross-resistance to atovaquone68 and compound instability related to a spontaneous
decomposition of the prodrug 1.20 into 1.21 [unpublished data]. Noteworthy, despite a
substantial similarity between floxacrine and 1.21, both compounds appear to have different
mechanisms of action with floxacrine inhibiting parasites via heme-mediated processes whereas
the single (S)-enantiomer of 1.21 was shown to be a highly selective inhibitor of the ubiquinol
oxidation site Qo of the P. falciparum bc1 complex.69
Recently, Riscoe and co-workers developed acridone T3.5 (1.22), a fully aromatized
THA analogue, which possesses excellent blood stage antimalarial activity via a dual mode of
action (Figure 1.16).70 Compound 1.22 was shown to be equipotent (RI ~ 1) in in vitro
erythrocytic assays against the chloroquine-sensitive D6 (EC50 = 45 nM) and the multidrug26

resistant P. falciparum strains Dd2 (EC50 = 77 nM) and also the atovaquone-resistant clinical
clone TM90-C2B (EC50 = 71 nM). 1.22 also showed suppressive in vivo efficacy in a P. berghei
murine model decreasing parasitemia by 95% at a dose
of 100 mg/kg per day. The curative effect was recorded
at higher doses (256 mg/kg per day). The dual mode of
action of compound 20 was attributed to the ability of
disrupting hemozoin formation (tricyclic aromatic

Figure 1.16: Chemical structure of
acridone T3.5

acridone core) as well as chemosensitizing via acid trapping. While no in vivo pharmacokinetic
data has been reported so far, the T3.5 acridone chemotype is a promising template for further
development of novel antimalarials.
1.6.3 SAR studies of 1,2,3,4-tetrahydroacridones
Finally, an extensive structure-activity relationship and structure-property relationship

Figure 1.17: SAR studies of 1,2,3,4-tetrahydroacridin-9(10H)-ones

study on more than 100 THAs was reported by Kyle and Manetsch.20 A systematic approach
following the Topliss operational scheme for aromatic substituents was applied to investigate the
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benzenoid ring while also looking at the saturated ring using the findings of Stephen and
Kesten.67 In general, the results (Figure 1.17) were similar to the previously observed structureactivity relationship data for the 4(1H)-quinolones (Figure 1.6). Despite the initial report from
Kesten on the importance of the mono-chloro substitution of the THA core, best antimalarial
activity was obtained when the C6 position was substituted with an electron-donating substituent
and C7 was substituted with a weakly electron-withdrawing group such as a halogen.
Substitutions at C5 and C8 were not well tolerated perhaps because of the disruption of
intermolecular hydrogen bonding between amine and carbonyl oxygen to the biological target.
The THA core containing a six member unsubstituted aliphatic ring was reported to be most
active. 7-Chloro-6-methoxy-1,2,3,4-tetrahydroacridin-9(10H)-one was reported with EC50 values
lower than 30 nM for the W2 and TM90-C2B strains. Although the THAs are less potent than
the 4(1H)-quinolones, the best THAs had an excellent in vitro therapeutic index and were
equipotent for the atovaquone resistant and susceptible strains. Unfortunately, the THAs suffered
from poor solubility and unfavorable microsomal stability yielding poor performance of the THA
analogues in vivo [rodent models, unpublished data]. Additional functionalization of acridin9(10H)-ones via alternative approaches such as prodrug or formulations are required to obtain
good oral efficacy.

1.7 Conclusions
4(1H)-pyridone and 4(1H)-quinolone chemotypes display potent antimalarial activities
against Plasmodium species in vitro and in vivo. Some of these chemotypes inhibit the electrontransport chain in P. falciparum and hence possess a mechanism of action similar to the one of
atovaquone. The progression of 4(1H)-pyridone GSK932121 into first-time-in-human studies
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featured the full potential that these chemotypes have, although the program had to be stopped
because of potential toxicity issues. Not surprisingly, several research groups focus their
resources in developing and optimizing 4(1H)-quinolone-based antimalarials. Recently, ELQ300 and structurally related 4(1H)-quinolone analogues have been shown be highly active
against P. falciparum and P. vivax at all life cycle stages. Due to this antimalarial activity profile
in conjunction with favorable pharmacokinetics, ELQ-300 has been selected as a preclinical
candidate in the MMV drug discovery program. At the same time, in vitro and in vivo efficacious
2-diheteroaryl 4(1H)-quinolones with dual mechanism of action have been developed, which
inhibit the NADH:ubiquinone oxidoreductase P. falciparum NDH2 and the cytochrome bc1
complex simultaneously. These 2-substituted 4(1H)-quinolones are currently undergoing further
development in the MMV pipeline.
Nevertheless, the development of 4(1H)-pyridone and 4(1H)-quinolone antimalarials are
also associated with risks. 4(1H)-Pyridones and 4(1H)-quinolones are known to be poorly
soluble and thus represent challenging drug candidates for pharmacokinetic and bioavailability
reasons. In addition, as the parasite electron-transport chain is quite often the biological target,
4(1H)-pyridone or 4(1H)-quinolone inhibitor design requires structural features inheriting a high
selectivity over the corresponding mammalian targets. Furthermore, the potential to induce
cross-resistance with atovaquone has to be carefully monitored during the optimization process.
In particular compounds with greatly reduced potential for inducing resistance (e.g., ELQ-300)
are required due to the high frequency of resistance selection with atovaquone. Also an ideal
antimalarial compound should have a rapid onset of action, which is a property none of the
compounds of this series has yet overcome. Despite these hurdles, the potent blood stage activity
and the demonstrated potential to kill hypnozoites in the gold standard P. cynomolgi infected
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Rhesus model makes the herein discussed 4(1H)-pyridones, the 4(1H)-quinolones, the THAs and
the PEQs attractive chemotypes for the development of novel drugs to treat multidrug resistant
malaria and to aid the malaria elimination campaign.
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CHAPTER 2: SYNTHETIC APPROACHES FOR THE CONVENIENT ACCESS
TO 3-ARYL-4(1H)-QUINOLONES1

2.1 Itroduction
Ethyl acetoacetate (EAA) is a versatile and well-established reagent in organic synthesis.
EAA's combined electrophilic and nucleophilic nature makes it a convenient reagent for the
preparation of a variety of products of different structural complexity. In medicinal chemistry, 2aryl substituted EAAs provide access to diverse classes of biologically active scaffolds such as
important heterocyclics. Various 2-aryl EAA derived compounds were well documented in the
literature as antifungal, antibacterial, antitubercular and antitumoral agents.1-4 These also served
as TNF-α inhibitors, α2C-adrenoreceptor antagonists, DMT1 blockers and HCV NS5B
polymerase inhibitors.5-8 In addition, a series of 3-aryl-4(1H)-quinolone compounds, synthesized
from corresponding aniline and 2-phenyl EAA, were reported to have excellent low nanomolar
activity against malaria.9 Notably, extensive development of this 3-aryl-4(1H)-quinolone
chemotype against P. falciparum and P. vivax malaria at all parasite life cycle stages resulted in
ELQ-300 (Figure 2.1), which recently entered preclinical studies.10 Based on the advantage and
importance of 2-aryl EAAs as starting materials, suitable and straightforward access to these
compounds is required.
Historically, 2-aryl EAAs are prepared using various metal-mediated and metal-free
reaction conditions.11-15 In a classical approach, 2-aryl-2-acylacetonitriles are converted to 2-aryl
1

The first part of the work presented has been submitted to Chem.Com. for review
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EAAs in two steps under harsh acidic conditions via an imidate intermediate in low to moderate
yields.11 Ethyl 2-arylacetate could also be acylated under basic conditions with acetyl chloride or
acetic anhydride to obtain the target compounds.12 These transformations, however, are lowyielding and produce the deacylated by-product (starting material), which in most cases is
inseparable from the EAA product. Finally, under Pd-mediated2c,

5c

or Cu-mediated

5d, 5e

conditions with the appropriate metal ligands, EAA could be treated with aryl halides and base to
obtain the target compounds at elevated temperatures. In turn, metal-catalyzed reactions suffer
from accompanying ligand arylations and product deacylation that is heavily dependent on the
nature and quantity of the base used. Moreover, minimal or no usage of expensive metal
catalysts is highly advisable in drug discovery because of malfunctions at the cellular level.16 All
of these facts prompted us to develop a protocol where the 2-aryl EAAs can be obtained easily
under mild metal-free reaction conditions.

2.2 Hypervalent Iodine Compounds
Hypervalent iodine compounds and diaryliodonium salts in particular have recently
captured the attention of synthetic chemists as mild and selective reagents.17 One of the biggest
advantages of the above mentioned salts is metal-free reaction conditions to overcome cost and
toxicity of the organometallic chemistry in medicinally interesting compounds. In recent
literature, arylation of carbonyl compounds and nucleophiles like O, N, S, Se, etc. under various
conditions was reported with excellent yields using highly electrophilic hypervalent
aryliodonium salts.18-24 Asymmetric synthesis via chiral iodonium salts is also being
investigated, although it is in the initial stages of research. With the inspiration of the above
mentioned successes, we were encouraged to extend the scope to a metal-free arylation of EAA.
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Noteworthy, the reaction between EAA and diphenyliodonium trifluoroborate to prepare 2phenyl EAA has been initially reported by a Soviet group in 1984.25 To our knowledge, the
arylation of EAA with diaryliodonium salts has not been explored by any research group since
this original report. Interestingly, a failed attempt of EAA reaction with diphenyliodonium salt
was reported in 1999.26 By the virtue of having one-pot synthetic access to various biaryl
iodonium salts and with some of them being commercially available nowadays, it was
envisioned that a general and simple arylation protocol can be established under mild
conditions.17

2.3 Arylation of Ethyl Acetoacetate (EAA) with Symmetrical Diphenyliodonium Salts
Diphenyliodonium tetrafluoroborate 2.1a was chosen as a test substrate in the
optimization of arylation reaction conditions resulting in 2-phenyl EAA in DMF with t-BuOK.
To avoid any possible solubility issues with iodonium salts, DMF was the solvent of preference,
though most of the salts with BF4 and OTf anions are soluble in nonpolar solvents. When 1:1
ratio of iodonium salt and EAA was used, the reaction was low yielding because of the formation
of double arylated products evident from LC-MS. However, improved yields were obtained
when 1:2.5 ratio of iodonium salt and EAA was used. On top, the formation of side products was
suppressed according to 1H-NMR analysis of the crude product. It was found that after reaction
completion, the addition of HCl solution in one portion is mandatory to avoid the formation of
deacylated product via a retro-Claisen reaction. Among the different bases screened, Cs2CO3 and
t-BuOK resulted in the best and most reproducible yields. Of the two bases, t-BuOK was
preferred due to its low cost. Later, having these conditions set, the influence of various
diphenyliodonium anions on the course of the arylation reaction was examined. Arylations with a
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diphenyliodonium triflate provided similar yields to the tetrafluoroborate, however, the
hexafluorophosphate resulted in a higher 60% yield. The reaction with an iodonium salt with a
bromide anion resulted in poor yields possibly due to a combination of competing
nucleophilicity of the bromide anion and the low solubility of the bromide salt in DMF.
Although the yield with the PF6 salt is slightly better than the arylations with BF4 and OTf
anions, it was preferred to proceed with the latter two due to their easy accessibility. Despite
initial moderate yields with the unsubstituted diphenyliodonium salt, we wanted to explore the
reaction further by probing diverse electron-rich, electron-deficient and sterically hindered
electrophiles with the reasonable assumption of getting improved results particularly when using
iodonium salts substituted at the aryl rings with electron withdrawing groups.

Table 2.1: Optimization of the arylation reaction conditionsa

Entry
Base
Time (h) XYield (2.2a) (%)b
1
t-BuOK
18
BF4 (2.1a) 53
2
Cs2CO3
20
BF4 (2.1a) 55
3
KOH
24
BF4 (2.1a) 35
4
K2CO3
28
BF4 (2.1a) 25
5
NaH
20
BF4 (2.1a) 40
6
t-BuOK
24
OTf (2.1b) 45
7
t-BuOK
24
Br (2.1c)
10
8
t-BuOK
24
PF6 (2.1d)
60
a
Reaction conditions: salt 2.1 was added to the enolate solution of EAA and the reaction was run for the tabulated
time. bIsolated yields combined in keto and enol form.

Firstly, various symmetrical iodonium salts with tetrafluoroborate or triflate anions were
prepared and subsequently treated with EAA under optimized conditions. The resultant 2-aryl
EAAs were then converted to the corresponding 3-aryl-4(1H)-quinolones under modified
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Conrad-Limpach conditions using 4-chloro-3-methoxyaniline.27 All the results are summarized
in Table 2.1.
Generally, arylations of numerous ortho- substituted substrates are problematic in metalmediated conditions and result in poor yields due to steric bulkiness.14 Remarkably, the orthosubstitution was tolerated well in our case with salts 2.1b and 2.1e getting converted to greater
than 70% of product signifying an advantage of the selected methodology. In addition, the
arylation

with

2,4-dimethyl

substituted

salt

2.1h

delivered

60%

yield,

whereas

dimesityliodonium example 2.1c resulted only in 10% yield. Noteworthy, compound 2.1c was
obtained in the enol form exclusively, impeding the formation of the enamine during the ConradLimpach cyclization. Unsurprisingly, increasing the substitution of the aromatic ring resulted in
slightly lower yields in the cyclization step due to steric factors (Table 2.2).
The arylation of EAA using electron-rich electrophiles like 4-tert-butyl took relatively
longer times and revealed marginally lower yields. Moreover, any attempts with 4-methoxy
substituted salt 2.1m did not deliver the required product even after prolonged reaction times.
The unreactivity of salt 2.1m is probably due to reduced electrophilicity of the iodine center. 4Chloro substituted salt 2.1f produced the corresponding product in respectable yields under these
reaction conditions. Noticeably, salts 2.1g and 2.1l, which contain deactivating groups, behaved
excellently, reacting to the corresponding arylated products in less time with yields over 90%.
Likely, these results can be linked to an enhanced electrophilicity of the iodine center.
Traditionally, the Conrad-Limpach reaction, which was initially reported in 188728, is
low-yielding and involves harsh conditions requiring high-boiling solvents like diphenyl ether or
polyphosphoric acid. In this report, we were able to improve the overall yields in average by
10% by using microwave assisted conditions in toluene as a solvent and cutting the cyclization
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time to 3 minutes (Table 2.2). Under classical high temperature thermal conditions in Ph2O the
formation of quinolone is usually accompanied with multiple side products which interfere with
isolation.

Table 2.2: Arylation of ethyl acetoacetate (EAA) with symmetrical saltsa

Entry
1
2
3
4
5
6
7
8
9
10

R
H (2.1a)
2-CH3 (2.1e)
2,4,6-tri CH3 (2.1f)
4-CF3 (2.1g)
2-F (2.1h)
4-Cl (2.1i)
4-tBu (2.1j)
2,4-di CH3 (2.1k)
4-COOCH3 (2.1l)
4-OCH3 (2.1m)

Yield 2.2b (%)
53 (2.2a)
73 (2.2b)
10 (2.2c)
93 (2.2d)
75 (2.2e)
70 (2.2f)
65 (2.2g)
60 (2.2h)
90 (2.2i)
No Reaction

Yield 2.3b (%)
60 (2.3a)
42 (2.3b)
No Reaction (2.3c)
62 (2.3d)
54 (2.3e)
68 (2.3f)
67 (2.3g)
38 (2.3h)
67 (2.3i)
N/A

a

Reaction conditions: a) t-BuOK, DMF, EAA, 5 to 21 h, r.t.; b) 4-chloro-3methoxyaniline, AcOH, benzene, DeanStark, 24 to 48 h, then MW, toluene, 3 min, 255 °C. bIsolated yields.

Switching the reaction solvent to toluene in a microwave allowed the isolation of analytically
pure samples by precipitation with no further need for recrystallization.

2.4 Arylation of EAA with Unsymmetrical Diphenyliodonium Salts
Next, the chemoselectivity trends were examined with unsymmetrical salts. A few
examples with varying sterics and electronics were prepared for this purpose followed by
treatment under optimized arylation conditions. The results are summarized in the Table 3.
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Table 2.3: Arylation of EAA with unsymmetrical saltsa

Entry
1
2
3
4

R
mesityl (2.1n)
4-NO2 (2.1o)
4-CF3 (2.1p)
4-Cl-3-pyridyl (2.1q)

Yield 2.2/2.2a (%)
2.2c/2.2a 36/0
2.2j/2.2a 83/0
2.2d/2.2a 89/0
2.2k/2.2a 50/12

Yield 2.3 (%)
No reaction (2.3c)
39 (2.3j)
62 (2.3d)
Trace (2.3k)

a

Reaction conditions: a) t-BuOK, DMF, EAA, 5 to 21 h, r.t.; b) 4-chloro-3-methoxyaniline, AcOH, benzene, DeanStark, 24 to 48 h, then MW, toluene, 3 min, 255 °C.

Excellent chemoselectivity was observed in the case of phenylmesityl substituted salt
2.1n, resulting in EAA 2.2c exclusively in 36% yield. The mesityl group was readily transferred
compared to the phenyl group. Compared to the symmetrical salt 2.1f, the improved yield for this
arylation may be due to the steric differences of both rings attached to the iodine center. During
the arylation of salts 2.1o and 2.1p, the electron-deficient rings were selectively and exclusively
transferred to produce the products 2.3j and 2.3d in excellent yields. Arylation with salt 2.1q
resulted in a 4:1 ratio of the pyridyl ring and phenyl ring products in 62% overall yield. However
the Conrad-Limpach cyclization of 2.2k did not perform well and produced only trace amount of
corresponding quinolone after several attempts of purification. Arylation pursuits using the 4anisylphenyl iodine compound to deliver the expected unsubstituted product 2.2a were not
successful. The observed chemoselectivity trends are consistent with selectivities reported in the
literature for metal-free reactions. The electron-poor rings are preferentially transferred over the
electron-rich rings and bulky rings readily transferred over rings lacking in sterics.
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2.5 Synthesis of ELQ-300 via Diphenyliodonium Salts
After having the arylation conditions set, this strategy was applied for the synthesis of
antimalarial compound ELQ-300 (Figure 2.1). The iodonium salt 2.6 was prepared according to
the reported procedure and subsequently treated with 4-iodophenol to obtain the biaryl ether 2.7
in excellent yield.18 Next, boronic acid 2.8 was prepared from aryl iodide 2.7 and converted
cleanly to the appropriate iodonium salt 2.9. The salt 2.9 was then treated with EAA under
standard arylation conditions providing the corresponding substituted EAA 2.10 in 52% yield in
its pure form of the keto-enol tautomers. This result is better than the previously reported

Figure 2.1: Synthesis of ELQ-300 via the hypervalent iodonium salt route
a) mCPBA, BF3·OEt2, DCM, 65%; b) 4-iodophenol, t-BuOK, THF, 0 °C – 40 °C, 90%; c) B(OiPr)3, BuLi, THF, 18 h,
90%; d) mCPBA, DCM, 80 °C, 10 mins; BF3·OEt2 8, 2 h, -78 °C to r.t., 56%; e) EAA, t-BuOK, DMF, 18 h, r.t. 52%; f) 4chloro-3-methoxyaniline, AcOH, benzene, Dean-Stark, 24 h then MW, toluene, 3 min, 260 °C 37%. Ar = (4(trifluoromethoxy)phenyl).

arylation obtained in the Cu-catalyzed reaction, where only 30% yield was obtained with the
contamination of inseparable deacylated product.29 Additionally, one equivalent of the
intermediate 7 is formed during the reaction, which could be reused to make the salt 2.9. Finally,
EAA 2.10 was treated under Conrad-Limpach conditions to obtain ELQ-300.
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2.6 Gram Scale Syntheses of Antimalarial 4(1H)-Quinolones ELQ-300 and P4Q-391
4(1H)-Quinolones belong to the well-established class of heterocyclic compounds being
approved by FDA for use in human primarily as antibacterials.30-32 4(1H)-quinolones have also
shown to be potent anticancer, antimicrobial and antiviral agents, with some natural products
containing a 4(1H)-quinolone scaffold inhibiting HIV integrase and interfering with
postintegrational processes.33-37 Recently, 3-alkyl and 3-aryl-4(1H)-quinolones have been
reported to possess excellent antimalarial activity in low nanomolar range.38, 39 Not surprisingly,
several research groups including our group focused their resources in developing and
optimizing 4(1H)-quinolone-based antimalarials.9, 40-42 Currently, ELQ-300 and its structurally
related 4(1H)-quinolone P4Q-391 (Figure 2.2) have been shown be highly active against P.
falciparum and P. vivax at all life cycle stages.10 Due to the antimalarial activity profile and
pharmacokinetics,
ELQ-300

has

been

selected by Medicines of
Figure 2.2: Structures of P4Q-391 and ELQ-300

Malaria Venture as a

preclinical candidate. In order to determine the safety profile required to nominate the candidate
entering preclinical development, large amounts of 4(1H)-quinolones ELQ-300 and P4Q-391
were needed. Herein, we report a practical and operationally simple gram scale syntheses of
ELQ-300 and P4Q-391.
For supplies during the initial lead optimization stages, we devised and executed an 8step synthetic route according to the reported procedures described in Figure 2.3.10,

40, 43

However, the utilization of expensive and harsh reagents made the method disadvantageous for
large scale preparations. In addition, the reported route is operationally tedious particularly for
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the purification steps. In contemplation of increasing the overall synthetic yields, decreasing the
number of synthetic steps, and reducing the expenses, alternative synthetic routes were explored.
In order to improve the preparation, the following issues were considered to be addressable:

1) The observed low-to-moderate yield was a result of the Ullmann couplings of
compounds 2.18 and 2.19. In particular, for the synthesis of the ortho-fluoro substituted biaryl
ether 2.19, which was used for the synthesis of P4Q-391, was only achieved in 39% yield.
Because the Ullmann-type coupling was the first step in the synthetic sequence, it contributed
profoundly for the low overall yields. An alternative to this reaction would ideally enhance the
final yield and avoid the usage of stoichiometric amounts of heavy metals.

2) The isolation and purification of the intermediates 2.13, 2.14, 2.18 and 2.19 were
commonly complicated requiring both flash chromatography purification and recrystallization.
Introduction of an aryl substitution in C2 position of EAA prior to the Conrad-Limpach
cyclization would not only simplify the purification step but also elude the use of the harsh acid
deprotection step.

3) The conditions for the Conrad-Limpach cyclization were sub-optimal lowering the
yields.28 In many instances, the cyclization of the crude enamine intermediate in high boiling
solvent results in a dark crude product, which was arduous to purify. Optimization of the
Conrad-Limpach cyclization step would definitely add to the overall synthetic outcome.
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Figure 2.3: Synthesis of ELQ-300 and P4Q-391 via Pd-catalyzed coupling
a) Na, Liq NH3; b) EAA, AcOH, benzene, Dean-Stark trap, reflux, overnight, then Ph2O, reflux, 15 min; c) I2, Na2CO3, MeOH;
d) Cs2CO3, DMF, EtI, rt, 12 h; e) CuI, Cs2CO3, 1-methyl-2-pyrrolidine, 18 h, 110 °C; f) n-BuLi, triisopropylborate, 3 h, -78 °C
then 6N HCl, 18 h; g) Pd(PPh3)4, 2M Na2CO3, DMF, 85 °C, 3 h; h) HBr, AcOH, reflux

Main optimization efforts first focused on alternatives to the low yielding metal-catalyzed
Ullmann coupling reaction. Hypervalent iodine compounds and diaryliodonium salts in
particular captured our attention as mild and selective reagents during the initial exploration.24
One of the biggest advantages using hypervalent iodine compounds were the metal-free reaction
conditions overcoming cost and toxicity issues related to the use of the organometallic reagents
in the initial approach. The correspondent diaryl iodonium salt was prepared following the
literature procedure as shown in the Figure 2.4.44 The corresponding iodobenzene 2.17 and
boronic acid 2.22 were treated with anhydrous mCPBA and BF3·OEt2 in dichloromethane
provided the corresponding clean iodonium salt 2.23 in 65% yield as a white solid which
required no further purification. This reaction was repeated several times at a 20 gram scale
without any hurdles. Subsequently, the arylation of phenols 2.15 and 2.16 with the iodonium salt
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2.23 using t-BuOK furnished biarylethers 2.18 and 2.19 in excellent yields after simple flash
chromatography with mere hexane.18

Figure 2.4: Synthesis of biarylethers via diaryliodonium salts
a) mCPBA, BF3·OEt2, DCM, 65%; b) phenol 2.15 or 2.16, t-BuOK, THF, 0 oC – 40 oC, 90%.

With the biarylether compounds in hand, the arylation of EAA was targeted (Figure 2.5).
The arylation of either diethylmalonate or EAA has been reported in the literature with different
halobenzenes.14,
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The copper-mediated reactions using the ligands such as L-proline or 2-

phenylphenol were also documented.14 The arylation attempts of biarylether 2.18 with EAA with
L-proline and CuI yielded trace amount of product along with an unwanted ligand arylation.
Surprisingly, the coupling reaction between EAA and aryl iodide 2.18 with CuI, Cs2CO3 and 2phenylphenol conditions provided the required product in 30% yield however with the
inseparable mixture of deacylated product, which was evident from NMR and MS analysis.45
The mixture of product was subjected to the traditional Conrad-Limpach cyclization conditions
producing ELQ-300 with 30% yield.28 Though the synthesis was done in four steps compared to
the route described in the scheme-I, the overall yield was 5.2%. The formation of product as
inseparable mixture with deacylated product was also an added disadvantage. At the same time,
the arylation reaction between EAA and the biarylether 2.19 for the synthesis of P4Q-391 was
unsuccessful. Alteration of catalysts, ligands, bases and solvents under various conditions did not
produce product presumably because of the ortho-fluoro substitution impact.
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Figure 2.5: Synthesis of ELQ-300 via Cu-catalyzed route
a) CuI, Cs2CO3, THF, 70 °C, 2-phenyl phenol, 30 h, 30%; b) 1) 3-chloro-4-methoxyaniline, AcOH, benzene, 100 oC, 24 h;
2) toluene, 265 °C, 3 min, 35%

Unsatisfied yields for the copper-catalyzed arylation in case of ELQ-300 intermediate
and the lack of formation of product with biaryliodide 2.19 for the synthesis of P4Q-391 led to
the development of an alternative strategy described in the Figure 2.6. Principally, the versatile
nature of 1,3-dioxin-4-ones of generating diversified building blocks in organic synthesis has
been well known and documented.46, 47 They act as protected enol forms of acetyl acetic acid and
thermal or photochemical ring opening with a choice of nucleophiles lead to variety of applicable
products. In the present scenario, 1,3-dioxin-4-one 2.26 was first iodinated at C5 position to
obtain 5-iodo-1,3-dioxin-4-one 2.27 and subsequently, the coupling of diarylether part was
performed.48 In this context, boronic acid 2.21 was treated with iodo compound 2.27 under Pdmediated conditions achieved 5-arylated 1,3-dioxin-4-one 2.31 product in 32% yield. To
circumvent the low yield, boronic acid 2.21 was converted to its air stable and more reactive
trifuoroborate 2.29 by treating with inexpensive KHF2.49 Then the coupling between
trifluoroborate 2.29 with iodo compound 2.27 under reported conditions resulted in much better
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yield of 70%.50 To our delight, the similar coupling reaction between 2.27 and borate salt 2.28
resulted in 91% yield and in both cases products were easily isolated with high purity. Next,
thermal ring opening of aryl substituted dioxinones 2.30 and 2.31 with ethanol in xylenes

Figure 2.6: Synthesis of ELQ-300 and P4Q-391 via a Cu-mediated coupling with 1,3-dioxin-4-one
a) NIS, AcOH, 70%; b) KHF2, MeOH, H2O, 70 oC, 24 h, 81% with 2.21 and 70% with 2.20; c) Pd2(dba)3, 2.27, K2CO3,
2:1 dioxane:water, 80 oC, (75 min and 91% with 2.28) and (4 h and 70% with 2.29) d) ethanol, xylenes, 120 oC, 5 h, 90%;
e) 1) 4-chloro-3-methoxy aniline, AcOH, benzene, Dean-Stark trap, reflux, 24 h; 2) toluene, 3 min, MV, 230 oC, 65% for
ELQ-300 and 81% for P4Q-391

revealed aryl substituted EAAs 2.24 and 2.25 in excellent yields (~90%).
Once the clean aryl substituted EAAs were obtained, the modification of the ConradLimpach conditions took place. As mentioned earlier, this reaction often resulted in low yields
for some substrates with isolation issues via a precipitation in high boiling diphenylether. First,
EAAs 2.24 and 2.25 were refluxed with 1.5 equivalent of 4-chloro-3-methoxy aniline under
acidic medium in dry benzene to produce the enamine intermediate. As a part of the
optimization, aniline related baseline impurities were removed by quick chromatography
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assuming that these contaminations were causing problems for the precipitation of the final
4(1H)-quinolone after the cyclization step. Reasonably clean enamine was also taken in toluene
instead of diphenyl ether, and subjected to microwave heating conditions at 265 oC for three
minutes. The 3-aryl-4(1H)-quinolone precipitated immediately and the reaction vials were placed
in -20 oC freezer overnight to allow the crystallization to complete. Much satisfactory yields of
65% and 81% were obtained for ELQ-300 and P4Q-391 respectively. The entire sequence for
the generation of both 3-diarylether-4(1H)-quinolones was checked and validated in multi-gram
scale gratifyingly without major issues.

2.7 Conclusions
In conclusion, to the best of our knowledge, a metal-free arylation on EAA using
diaryliodonium salts was broadly studied for the first time. Commercial availability or
straightforward accessibility of iodonium salts makes this method convenient and operationally
simple. The arylation with symmetrical salts with electron-rich rings delivers good yields with
the exception of the reaction with 4-methoxy substituted aryliodonium salt. Furthermore,
excellent results are obtained with symmetrical salts containing electron-deficient rings.
Importantly, the moderate yields of arylations using ortho-substituted iodonium salts stands in
stark contrast to metal-mediated synthetic approaches with similar substrates, which usually do
not perform well. Finally, impressive chemoselectivities were also obtained in the case of
unsymmetrical salts. Overall this method demonstrated enhanced selectivity and versatility
giving straightforward access to medicinally and pharmaceutically interesting EAA derived
complex molecules.
Also a first multi-gram scale synthesis for antimalarial compounds ELQ-300 and P4Q391 has been accomplished in good overall yield. All the reactions in the sequence are
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operationally simple and having high value of reproducibility. This route is enriched with high
yielding reactions particularly arylation of phenol with iodonium salt, modified Conrad-Limpach
conditions and clean aromatic and aliphatic Suzuki-Miyuara coupling reactions.
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CHAPTER 3: STRATEGIES TO IMPROVE AQUEOUS SOLUBILITY AND
BIOAVAILABILITY OF ANTIMALARIAL 3-ARYL-4(1H)-QUINOLONES

3.1 Introduction
Despite recent decrease in global morbidity and mortality caused by malaria, it remains a
dangerous parasitic disease with over 200 million infection cases reported and an estimated 0.6
million of deaths in 2012.1 Children under age of five are accounted for almost 80% of
documented mortality cases with the majority of deaths occurring in sub-Saharan Africa. Five
species of the genus Plasmodium (P. falciparum, P. vivax, P. ovale, P. malariae, and P.
knowlesi) are responsible for malaria in humans and P. falciparum is the most dangerous one
often being lethal. Importantly, the dormant liver stages that exist in P. vivax and P. ovale are
usually underestimated, however those are capable of relapsing blood stage malaria at a later
time without a mosquito bite. As of 2012, parasite resistance to one of the most widely used
antimalarial chloroquine has been confirmed in ten countries making artemisinin combination
therapies (ACTs) the last resort medicine to combat P. vivax malaria.1 Unfortunately, resistance
to artemisinin has already emerged at least in four countries of South-East Asia and there is an
urgent need for new antimalarial drugs to overcome documented resistance and at the same time
be readily bioavailable due to economic reasons.2,

3

Commonly, antimalarial drug discovery

focuses on the erythrocytic stages of malaria that cause disease. Yet to eliminate malaria,
compounds are required to target exoerythrocytic stages, namely the liver stages as well as the
infectious stages for mosquitoes. Recent reevaluation and optimization studies of 4(1H)63

quinolones,4 4(1H)-pyridones,5 1,2,3,4-tetrahydroacridones,6 4(1H)-quinolone esters7, 2-aryl4(1H)-quinolones,8 and 3-carboxyl-4(1H)-quinolones9 led to new probes with promising in vitro
erythrocytic stage activity and improved physicochemical properties. Particularly, 3-phenylsubstituted 6-chloro-7-mehthoxy-4(1H)-quinolones (P4Qs) identified by Riscoe and our group
have been shown to be potent in vitro against the clinically relevant isolates of P. falciparum W2
(chloroquine and pyrimethamine resistant) and TM90-C2B (chloroquine, mefloquine,
pyrimethamine and atovaquone resistant) with EC50 constants in the single digit nanomolar
range.4, 10, 11 Moreover, these compounds have also been tested against J774 mammalian cells
demonstrating to inhibit parasite growth over mammalian cells with a selectivity of 50 or greater.
Further optimization lead to 4(1H)-quinolones P4Q-391 and ELQ-300, which have been shown
to not be only potent against blood stages and liver stages of the parasite, but also efficient at
blocking transmission.
During the optimization, a variety of P4Qs with acceptable microsomal stability and
good membrane permeability have been identified, which motivated us to test frontrunner
compounds P4Q-95, P4Q-146 and P4Q-158 (Figure
3.1) first for in vivo efficacy against the blood stages
in a modified Thompson test and against the liver
Figure 3.1: 3-aryl-4(1H)-quinolone
frontrunner compounds tested for in vivo
efficacy in various models

stages using a GFP expressing P. berghei strain. As a
result, compounds P4Q-158 exhibited respectable

suppressive in vivo activity against the liver and the blood stages whereas P4Q-146 was slightly
active and P4Q-95 appeared to be completely inactive (Table 3.1).
Both compounds P4Q-146 and P4Q-158 are slightly more in vitro active than P4Q-95,
nevertheless they are either better soluble (increasing aqueous solubility by “out-of-plane” aryl
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substituent due to o-methyl group in P4Q-146) or metabolically more stable (blocking of
metabolically labile site by CF3-group in P4Q-158). In addition, 3-aryl-4(1H)-quinolone leads
exhibited gametocidal activity as shown by significant reduction or complete inhibition of oocyst
development in mosquitoes (average number for untreated gametocyte 15.3, Table 3.1) and
reduction of the average number of exflagellation per field (data not shown).12 Compounds were
also tested against EE stages of malaria, with P4Q-158 was highly potent against liver stage
parasites, while P4Q-146 was unable to effectively prevent the development of liver stage
parasites in vivo.13
Table 3.1: Biological and physicochemical properties of frontrunners compounds P4Q-95, P4Q-146 and P4Q-158
Compound

P4Q-95

P4Q-146

P4Q-158

W2 EC50 (nM)
TM90-C2B EC50 (nM)
RI = EC50(C2B)/EC50(W2)
Cytotoxicity J774 EC50 (mM)
CI = EC50(J774)/EC50(C2B)
Log D7.4
Permeability Pe pH=7.4 (10-6 cm/s)
Solubility pH=7.4 (µM)
MW (g/mol)
Microsomes human T½ (min)
Microsomes mouse T½ (min)
Microsomes rat T½ (min)
Bioavailability, F%
In vivo: parasitemia suppression on day 6PE (%)
Transmission blocking potential
(average number of oocysts)

26.2
15.3
0.58
> 33.4
> 2,184
2.8
48.3
5.7
299.7
99.5
45.8
135.3
<2
not active

5.83
4.03
0.69
> 31.9
> 7,908
2.5
191
8.7
313
70.8
24.0
59.1
<2
17

12.0
6.6
0.5
>27.2
>4,102
2.3
3.0
0.3
367
min degrad.
min degrad.
219
~3
92

0.1

0.0

n.d.

In order to support our hit-to-lead optimization efforts of this important class of
antimalarials, we decided to investigate in details why these frontrunner compounds displayed
such significant differences in the various in vivo efficacy assays. Subsequent pharmacokinetic
studies with lead quinolone compounds suggest the aqueous solubility is the major reason for
poor bioavailability and moderate in vivo activity. Interestingly, a few advanced 4(1H)quinolones of the series, ELQ-300 and structurally related analogue P4Q-391 (Figure 3.2), have
been recently shown be highly active against P. falciparum and P. vivax at all life cycle stages.14
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ELQ-300 has been selected as a preclinical candidate in the MMV drug discovery program and
currently placed in preclinical development. Despite of
excellent antimalarial profile ELQ-300 also lacks in
aqueous solubility.14 Moreover, the absence of doseproportionality caused by low solubility impedes the
determination of the therapeutic index and in vivo toxicity.

Figure 3.2: Chemical structures of
preclinical 4(1H)-quinolones ELQ-300
and P4Q-391

Herein, we report quantum mechanics (QM) torsion profile calculations,

13

C T1 spin-

lattice relaxation experiments, as well as X-ray studies conducted with the objective to determine
structural modifications improving P4Q's physicochemical properties such as solubility resulting
in an increased bioavailability. We also describe the development of prodrug approaches to
circumvent the observed bioavailability limitations. Prepared prodrugs have been tested for
chemical stability and aqueous solubility at different pHs. In a P. berghei infected mouse model,
the three most promising prodrugs have subsequently been shown to be more in vivo efficacious
than their corresponding parent compounds. Finally, the increased antimalarial activity of these
prodrugs was demonstrated to be derived from the significantly improved oral bioavailability.
Most importantly, the herein presented prodrug approaches are easily applicable in any
antimalarial 4(1H)-quinolone or 4(1H)-pyridone scaffolds with limited oral bioavailability.9, 15, 16

3.2 Disruption of 3-Aryl-4(1H)-Quinolones’s Molecular Planarity and Symmetry
3.2.1Rotational barrier calculations
As the main structural difference between P4Q-95 and P4Q-146 is the methyl group in
ortho-position of the 3-phenyl ring, the rotational barriers along the C3-C12 bond of both 3-aryl66

4(1H)-quinolones were first established using quantum mechanics (QM) calculations by
technique previously described (Figure 3.3).13 Relaxed dihedral angle scans (starting with 0˚
when both methyl group of P4Q-146 quinolone and o-methyl-3-phenyl are directed towards each
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Figure 3.3: Quantum mechanics energy profile for P4Q-95 and P4Q-146

other in the same plane) with a torsion angle increment of 15˚ were carried out employing a
HF/6-31G** method using Jaguar application in Maestro suite (version 9.2, Schrödinger, Inc).
The structures were optimized prior to the torsion scan using the same level of theory. The
torsion profile was then obtained by plotting 24 energy points versus dihedral angles.
Previously, the calculated rotational barrier ΔErot of 20 kcal/mol was reported as a
suitable threshold between atropisomers and non-atropisomers.17 The prediction accuracy of QM
calculations is 86% over experimental values and makes it therefore a practical tool to predict
atropisomerism along the drug discovery process. Based on the QM energy profile obtained for
P4Q-95, the lowest energy barrier ΔErot that allowed the interconversion between geometrical
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isomers was 11.9 kcal/mol. This result suggested that P4Q-95’s torsional rotation half-time at
room temperature was in the order of milliseconds with a free rotation along C3-C12 bond
completely lacking of any axial chirality. In contrast, the minimal energy barrier ΔErot of P4Q146 has been calculated to be 23.2 kcal/mol implying that the half-time for the same bond
rotation was in the range of hours. Compounds with torsion angel rotational energy barriers ≤ 30
ΔErot ≥ 20 kcal/mol have the potential to form atropisomers with corresponding interconversion
half-lives (t1/2) in the order of minutes to months. According to the classification proposed by
LaPlante and co-workers,13 P4Q-95 is a symmetrical compound with a rapid free rotation along
C3-C12 bond and belongs to the Class 1 of the atropisomers classification. On the other hand,
P4Q-146 is experiencing delayed axial interconversions and corresponds to the Class 2 of
compounds, however, should be developed as a stereoisomer mixture as long as the racemization
is faster relative to the in vivo elimination rates.
Leaving the atropisomer discussion aside, the significantly increased rotational energy
barrier of P4Q-146 suggested also a more orthogonal orientation of the 3-aryl substituent relative
to the 4(1H)-quinolone plane. QM calculations evoked that in comparison to P4Q-95, the out-ofplane 3-aryl ring of P4Q-146 likely alters the molecular crystal packing increasing the aqueous
solubility. In fact, the aqueous solubility determined by an HPLC protocol in our group, revealed
a 1.5-fold increase in solubility for 2-methylphenyl substituted 4(1H)-quinolone P4Q-146 over
P4Q-95 (solubility P4Q-95 ~ 5.7 µM; P4Q-146 ~ 8.7 µM). Introduction of the ortho-substituent
into the 3-phenyl ring of the 4(1H)-quinolone is indeed changing the overall energy profile of the
molecule and could be used as one of the medicinal chemistry’s tools to enhance bioavailability.
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3.2.2 Spin-lattice relaxation experiment
To further substantiate our out-of-plane findings, NMR-based experiments measuring the
relaxation times were conducted.

13

C spin-lattice relaxation T1 values are excellent parameters
for

monitoring

relatively

slower

segmental motion or flexibility of C-H
vectors.18

We

used the

inversion

recovery technique using inverse-gated
Figure 3.4: 13C spin-lattice relaxation T1 values for two
frontrunner compounds P4Q-95 and P4Q-146

rotation of the C3-C12 bond by determining all

proton
13

decoupling

to

inspect

the

C T1 values of the compounds P4Q-95 and

P4Q-146 (see the Supporting Information for details). The moiety motion of 3-aryl-4(1H)quinolone compounds were compared using the determined T1 values (Figure 3.4). Shorter times
are characteristic of a relatively slower fragment motion and decreased flexibility.18 Since the T1
values of quinolone P4Q-95 were ~0.2 seconds shorter than the ones of P4Q-146 (the average
values are 0.5 seconds versus 0.7 seconds), it can be concluded that the 3-aryl ring of P4Q-146 is
more rigid. These results support our QM energy calculations indicating that the C3-C12 bond
rotation of P4Q-146 is slower.
3.2.3. X-ray studies
Finally, X-ray studies were conducted to confirm different crystal packings depending on
whether a P4Q possesses atropisomeric character or not (Figure 3.5). Based on the fact of
elevated melting points of P4Q class (m.p. > 230 ºC), the poor solubility could be attributed to
the high crystallinity of the molecule.19 Although the hydrogen bonding distances between the
quinolone’s oxygens and nitrogens are similar for P4Q-95 (2.800 Å) and P4Q-146 (2.687 and
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2.808 Å), linear molecule chains have
been observed in the crystal of P4Q-146,
whereas for P4Q-95 a zigzag-like packing
P4Q-95

P4Q-146

was determined. Moreover, for P4Q-95,
the density was 6.7% higher than the one
of P4Q-146 suggesting that the additional
methyl group of P4Q-146 prevents an
efficient packing and hence disrupt the
intermolecular interactions led to the high

Figure 3.5: Crystal packing of two frontrunner
compounds P4Q-95 and P4Q-146

crystallinity. It has been shown before, the

disruption of molecular planarity is effective method of increasing aqueous solubility to up to
350-fold improvement.20 In order to free a molecule from its crystal in case of high packing, an
elevated level of free energy is required. The difference in energy must be indemnified by the
release of solvation energy during the solvation step. Basically, performed X-rays studies are in
accordance with the QM calculations and the spin-lattice NMR experiment confirming the
disturbance of molecular crystal packing for the 3-phenyl-4(1H)-quinolone chemotype with the
installation of the ortho-substitution.

3.3 Prodrug Approaches
3.3.1 Introduction and synthesis
There are no big surprises of 3-aryl-4(1H)-quinolones being poorly soluble as more than
30% of all drug discovery compounds have been reported with a reduced solubility of 10 µM
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and lower.21 Decreased aqueous solubility
has been identified as one of the most
critical parameters limiting the therapeutic
use of a variety of drug candidates. The
formulation techniques such as the use of
solubilizing agents, salt formation and
particle size modification are commonly
utilized to overcome solubility barriers,
Figure 3.6: Prodrug strategies applied to P4Q class

however often these cannot provide
sufficient improvements. It has been also shown by other groups19 that an enhanced water
solubility and an improved oral bioavailability may be achieved by impinging the crystal packing
or by decreasing the melting point of the lead compound. The development of prodrugs –
deliberately modified forms of the active ingredient that can undergo an enzymatic and/or
chemical transformation in vivo – is an alternative and well-documented approach to increase
aqueous solubility and bioavailability.

19, 21, 22

Interestingly, approximately 10% of world

marketed drugs are classified as prodrugs with about a third of new molecular entities (NME)
approvals folded into this category in 2008.21 Prodrugs typically developed via chemical
modification of activated functional groups into esters, ethers, carbonated, carbamates, oximes,
amides and phosphates.
In the case of 4(1H)-quinolones, the keto form is favored over the enol form in both solid
and solution states.23 It was shown by our group, that methylation of P4Qs occur almost equally
at both N1 and O4 site of quinolone.4 However, the alkylation using alkyl halides with two and
more carbons yielded the O-substituted products exclusively. These results enabled us to use the
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hydroxyl group of the 4-quinolinol as a development point for a prodrug approach (Figure 3.6).
We first decided to derivatize the 4-hydroxy group of the P4Qs via a simple
esterification/acylation with the assumption of altering the intermolecular hydrogen bonds of
4(1H)-quinolones disrupting the high crystallinity of the compounds. The synthesis of ester,
carbamate and carbonate 4(1H)-quinolones was straightforward using cesium carbonate as a base
in DMF yielding the desired products in moderate to good yields (Figure 3.7A). 3-Aryl-4(1H)quinolones were prepared as previously described via a Conrad-Limpach cyclization of 2-aryl
substituted ethyl acetoacetate with 3-chloro-4-methoxy aniline.

Figure 3.7: Synthesis of 4(1H)-quinolones and prodrugs via O-alkylation/acylation
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3.3.2 Prodrug’s antimalarial activities and structure-property relationship (SPR) studies
The synthesized compounds were tested against the clinically relevant multi-drug
resistant malarial strains W2 (chloroquine and pyrimethamine resistant) and TM90-C2B
(chloroquine, mefloquine, pyrimethamine and atovaquone resistant).4 The human malaria
parasite P. falciparum was grown in vitro in dilute human erythrocytes in RPMI 1640 media
containing 10% heat inactivated plasma and the potency for each 4(1H)-quinolone prodrug has
been calculated against the individual strains as the 50% effective concentration (EC50).
In parallel to the in vitro antimalarial activity testing, standard physicochemical
properties were determined to identify potential compound liabilities. All compounds were
assessed for aqueous solubility and partition coefficient LogD using HPLC-based protocols,
which were previously described.4 Passive transcellular permeability was determined using the
standard parallel artificial membrane permeability assay (PAMPA).
The summary of antimalarial in vitro activities and physicochemical properties are shown
in Table 3.2. Generally, introduction of ester (P4Q-464) and carbonate (P4Q-463) groups into
O4 position of P4Q-146 has not affected the biological activities but at the same time increased
the lipophilicity of the molecule. More importantly, implemented promoieties did not improve
the aqueous solubility which was the primary objective of our prodrug approach. Installation of a
carbamate into 4(1H)-quinolone (P4Q-413 and P4Q-465) did not affect the solubility either,
while permeability was increased by more than 10 times. Surprisingly, carbamates derivatives
were also completely inactive against P. falciparum using in vitro cellular assay.
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Table 3.2: In vitro antimalarial activities and SPR data for P4Q-146 prodrugs
SAR
EC50, [nM]
Name

SPR
pH 7.4

MW
TM90C2B

W2
P4Q-146

-H

Solubility
[µM]

PAMPA
Pe 10-6

LogD

313.8

5.8

4.0

8.7

191

2.5

P4Q-464

369.8

3.3

0.9

2.9

143

4.9

P4Q-463

385.8

2.4

8.8

0.5

504

4.2

P4Q-413

412.9

>6054

3240

0.03

1237

2.6

P4Q-465

410.9

2185

1379

2.9

1555

2.8

P4Q-366

401.8

8.8

1.4

0.1

46

4.6

P4Q-351

429.9

7.3

1.9

1.6

100

5.3

P4Q-369

445.9

16.3

2.9

52

430

2.5

P4Q-414

495.4

19.4

12.6

35

194

3.2

P4Q-427

494.4

not stable

not stable

N/A

N/A

N/A

P4Q-428

508.4

not stable

not stable

N/A

N/A

N/A

3.3.3 pH-Triggered prodrugs
In the classical prodrug approach, covalent linkage between the parent drug and prodrug
moiety is cleaved through an enzymatic hydrolysis. For example, almost half of all marketed
prodrugs are activated this way with the majority been esters.22 Various esterases found in the
blood, liver and other tissues are responsible for the cleavage of the ester bond. Significant
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differences in specific animal enzyme activities,
Latent

Spacer

Nu

however, challenge the accurate prediction of parent

Activated

compound release in vivo. The phosphate is the only

Spacer

Nu

prodrug that typically hydrolyzed at similar rates in
Nu = OH, NHR, S

different species by alkaline phosphatase. On the
+

Drug - OH

other side, despite the satisfactory chemical stability,
phosphates could lead to the precipitation of parent

Figure 3.8: pH-Activated prodrugs

compound in the intestinal lumen.22
An alternative approach that can regenerate the parent compound via chemical methods
has been identified as a superior way to avoid inter- and intraspecies variability involved with
enzymatic activities. For example, regeneration of the active drug can be accomplished via a pH

P4Q-414
120.0

%remaining

100.0
80.0
SGF
60.0

pH2
pH5.5

40.0

pH6.5
pH7.4

20.0
0.0
0

20

40

60

80

100

120

140

time, min

Figure 3.9: Aqueous stability of P4Q-414 at different pHs
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mediated process of cyclization-activated prodrugs.24 Ideally, such a prodrug moiety would
consist of a latent nucleophile which is not activated at a pH range 1-5 (GIT pH) and undergo a
controlled intramolecular cyclization releasing the parent drug once the pH is elevated (Figure
3.8).
To avoid an animal-patient dependence associated with an enzymatic cleavage and the
same time develop a prodrug which would be chemically stable at low pH and soluble in water,
we designed carbonate prodrugs P4Q-369, P4Q-414 and carbamates P4Q-427 and P4Q-428. In
theory, the nucleophilicity of the amine nitrogen is controlled by pH level of a solution and been
fully protonated at acidic pHs. The same nitrogen would attack the electrophilic carbon on
carbonate (carbamate) when the pH level increased, forming either a 5- (P4Q-369, P4Q-427) or
6- member (P4Q-414, P4Q-428) ring. The reaction is controlled by both acid-base equilibrium
and the rates of new ring formation.
The synthesis of Boc-protected alkyloxycarbonyloxymethyl (AOCOM) halides was
accomplished as reported before in good yields (Scheme 1B).

25

Corresponding alkyl halide was

reacted with P4Q compound in presence of base to give AOCOM phenolic prodrug which upon
deprotection yielded water-soluble HCl salts P4Q-369, P4Q-414, P4Q-427 and P4Q-428. High
decomposition rates to parent P4Q-146 of carbamates P4Q-427 and P4Q-428 at low pHs was
noticed upon deprotection of AOCOM prodrug and this pair was abandoned from further
development. In contrast, carbonate AOCOM analogues (P4Q-369, P4Q-414) showed excellent
aqueous stability-release profiles (Figure 3.9). The stability was assessed in buffers with different
pHs (2, 5,5, 6.5 and 7.4) and simulated gastric fluid (SGF) and quantified by LCMS. According
to the profile received, P4Q-414 is stable at the pH level 2 - 5.5 and start decomposing at pH ~
6.5 (35 % decomposition in 2 hours). Fast release (100% in 1 hour) of parent compound P4Q76

146 is occurring when pH is raised to 7.4. Generally, the stability of P4Q-414 at physiological
stomach pHs and its rapid release at pH > 7 is optimal for development of cyclization-activated
prodrugs.
3.3.4 In vivo efficacy of selected prodrugs P4Q-146 and P4Q-158
Three 4(1H)-quinolones prodrugs of each P4Q-146 and P4Q-158 were selected to
undergo screening for in vivo efficacy based on improved aqueous solubility. P4Q-158 was
chosen as the parent compound possessed enhanced microsomal stability resulting from the
para-substituted CF3 group. Compound P4Q-146 seemed to be a good candidate derived from
the out-of-plane substitution effect. The screen involved treating mice once per day with 10
mg/kg or 50 mg/kg of test compound delivered in 1% HEC on days 3 through 5 of post-exposure
and then assessing parasitemia on days 6 post-exposure. Compounds with greater than 50%
inhibition of parasitemia on that day were considered to be active.
Table 3.3: In vivo efficacy of P4Q-158 and P4Q-146 prodrugs

Compound
(Route)
P4Q-146 (po)
P4Q-369 (po)
P4Q-414 (po)
P4Q-594 (po)
P4Q-158 (po)
P4Q-621 (po)
P4Q-435 (po)
P4Q-595 (po)

10 mg/kg
% Suppression Day
Day of death
6PE
(avg)
29
13
71
16
52
13
39
15
11
14
75
13
82
13
39
16

50 mg/kg
%Suppression Day
Day of death
6PE
(avg)
28
13
46
13
72
13
54
15
10
13
96
16
96
14
12
15

Suppression activity of six prodrugs and parent compounds P4Q-146 and P4Q-158 is
summarized in Table 3.3. pH-triggered AOCOM prodrugs of P4Q-158 with both two and three
methylene bridge were the most active compounds displaying over 95% inhibition at day 6 post77

infection at higher dose. Reduced in vivo efficacy averaging a 75% inhibition and 82% inhibition
day 6 post-exposure was observed for P4Q-158’s prodrugs at lower dose 10 mg/kg. At the same
time, compounds P4Q-414 and P4Q-369 derived from early lead P4Q-146 were not that active,
however still possessed suppressive activities. Surprisingly, phosphate prodrugs of both P4Q158 and P4Q-146 were not better than parents’ compounds suggesting delivery issues.
3.3.5 In vivo pharmacokinetics
In vivo PK experiments were performed in order to assess the systemic exposure in mice

PK profile (10mg/kg)
100

conc [uM]

10

Prodrug1
Prodrug2
Prodrug3
P4Q-158

1

0.1

0.01

0.001
0

4

8

12
16
time [hrs]

20

24

28

Figure 3.10: Plasma concentration of P4Q-158 and P4Q-158 prodrugs at different time points. Each point
was measured in triplicated and each time point is an average of five mice.

following oral administration of P4Q-158. Mouse plasma was collected via cardiac puncture at
different time-points (0.5 hr, 1 hr, 2 hr, 4 hr, 24 hr) post-treatment with experimental compound
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at a dose of 10 mg/kg and analyzed by LCMS (QqQ Agilent 7830) (Figure 3.10). P4Q-158 was
slowly absorbed after oral administration, with maximum plasma concentrations being observed
120 min post-dose, and concentrations remained above the lower limit of quantification (LLQ)
up to ~24 h post-dose. Nevertheless, the maximum plasma concentration (Cmax) of P4Q-158 has
never passed 365 nM. Introducing of pH-sensitive moieties in prodrug P4Q-621 and P4Q-435
significantly improved maximum plasma concentration (12 µM and 21µM accordingly) and
more importantly increased the AUC value in 35 and 50 folds respectively. The PK profile for
phosphate prodrug revealed a maximum plasma concentration of ~1 µM with an AUC value
even lower than the parent P4Q-158. The poor PK performance of the phosphate is in
accordance with in vivo efficacy data and could be explained by stability issues.
Table 3.4: PK parameters of P4Q-158 and P4Q-158 prodrugs
P4Q-158

P4Q-621

P4Q-435

P4Q-595

MW

367.75

535.34

549.37

521.72

Dose [mg/kg]

10.00

10.00

10.00

10.00

Cmax [µmol/L]

0.36

11.99

21.21

1.11

Tmax [min]

120

240

60

60

AUC 0 --> inf [min*µmol/L]

223

8033

11665

121

Vd [L/kg]

75.53

1.56

0.86

17.27

Cl [mL/min/kg]

121.94

2.33

1.56

158.41

t1/2 apparent [hrs]

7.15

7.74

6.35

1.26

Notably, all four compounds are cleared from the system in less than 24 hours which
could be accounted by the accelerated metabolism of parent 4(1H)-quinolone. In order to be
curative, however, antimalarial compound must stay in the blood for at least 36 hours.
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3.4 Conclusions
The potent blood stage activity and demonstrated potential to kill hypnozoites in the gold
standard P. cynomolgi infected Rhesus model make the P4Qs attractive chemotypes for the
development of novel drugs to treat multidrug resistant malaria, to eradicate EE stages, to block
transmission, and to aid the malaria elimination campaign. At the same time, the major liability
of P4Qs class of compounds is low aqueous solubility and as a result unacceptable
bioavailability. Both disrupting of crystal packing and prodrug approaches were employed to
overcome solubility hurdles. QM rotational barrier calculations and NMR-based experiments
confirmed rotational energy increase with implementation of methyl group into ortho- position
of 3-phenyl ring. X-ray analysis of P4Q-95 and P4Q-146 also revealed that the dihedral angle
for P4Q-95 is approaching 180°, while the ortho-methyl-phenyl group in P4Q-146 is completely
orthogonal (Ф = 90°) to the quinolone plane . These results confirm that structural modifications
altering the crystal packing improving the aqueous solubility. As an alternative, we have
developed a prodrug approach, in which the prodrug is highly soluble and a parent compound is
released by a pH-triggered mechanism. A selected set of prodrugs has been shown to possess
improved in vivo antimalarial efficacy in a P. berghei infected mouse. The efficacy data was
confirmed by pharmacokinetic profiling of pH-trigger prodrugs in vivo.
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SUMMARY

Among the priorities in antimalarial drug research is the development of a drug
candidate, which has potential to be used for single exposure radical cures. The majority of
antimalarial chemotypes being currently in development target the erythrocytic stages of the
disease but lack potent activity against the liver stages and the mosquito stages of malaria. This
challenge is aggravated by the lack of rapid and well-validated assays to assess liver stage
activity as well as transmission blocking activity. Yet, to eliminate and completely eradicate
malaria, antimalarial compounds are required to target these three stages of the parasite lifecycle.
Moreover, new antimalarial drugs have to be readily orally bioavailable and at the same time
have to overcome documented resistance. Currently, there are about a dozen of new antimalarial
candidates in the early clinical phases of drug development. However, of these few promising
compounds, only a few of these are potent at targeting multiple stages of the malaria parasite.
One of these promising candidates is ELQ-300, which is structurally related to the 4(1H)quinolone class of compounds.
Recent reevaluation and optimization studies of 4(1H)-quinolones lead to new probes
with potent in vitro erythrocytic stage activity and improved physicochemical properties.
Particularly, 3-phenyl-substituted 6-chloro-7-mehthoxy-4(1H)-quinolones (P4Qs) have been
identified by Manetsch and Kyle to be in vitro active against the clinically relevant isolates of P.
falciparum including atovaquone resistant strain with EC50 constants in the single digit
nanomolar range. These compounds have also been tested against J774 mammalian cells
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inhibiting parasite growth over mammalian cells with a spectacular selectivity factor of 50 or
greater. More importantly, radical cures were achieved in vivo while evaluating efficacy with
selected 3-aryl-4(1H)-quinolones at doses as low as 3 mg/kg and 1 mg/kg. Additional
optimization led to 4(1H)-quinolones P4Q-391 and ELQ-300, which have been shown to be
equally potent in all three stages of malaria lifecycle.
Nomination of a preclinical candidate requires its availability in large amounts in order to
properly determine the safety profile. We have developed a practical and operationally simple
gram-scale syntheses of both ELQ-300 and P4Q-391, which was used for the synthesis of
multiple grams of selected 4(1H)-quinolones. In parallel, a clean arylation protocol of ethyl
acetoacetate was developed, which uses hypervalent diaryl iodonium salts under mild and metalfree conditions. The scope of this reaction using symmetric and unsymmetric iodonium salts
varying in sterics and electronics was examined. Furthermore, this synthetic approach has been
applied for the synthesis of the preclinical candidate ELQ-300.
Notwithstanding, low aqueous solubility and unacceptable pharmacokinetic and
bioavailability profiles are considered to be the major drawbacks of the P4Q class of compounds.
The bioavailability is a function of the fraction absorbed and the clearance of the compound. At
the same time, absorption is largely impacted by physicochemical properties such as
permeability, solubility and dissolution rate. Poor solubility is not only limiting the absorption of
the compound to the blood but also causing the absence of dose-proportionality required for the
determination of the therapeutic index and in vivo toxicity. Noteworthy, the deficient solubility
of 3-aryl-4(1H)-quinolones is common for experimental candidates as about 40% of all drug
candidates produced from high-throughput screenings are poorly soluble. A variety of techniques
such as salt formation, particle size reduction and introduction of solubilizing agents have been
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used to overcome these barriers. However, such an increase in solubility is rather temporary,
causing the solute to reverse to its crystal form, which is thermodynamically more stable. The
strategies of introducing hydrogen bond donating or accepting groups into the molecule are
commonly used to improve the aqueous solubility. The disruption of molecular planarity or
molecular symmetry is alternatives yet underutilized strategies to enhance solubility. Moreover it
is more universal and could be more effective than a decrease in lipophilicity. For the selected
P4Q frontrunners P4Q-146 and P4Q-158, quantum mechanics torsion profile calculations,

13

C

T1 spin-lattice relaxation experiments as well as X-ray studies were conducted with the objective
to determine possible effects improving key physicochemical properties such as solubility and
stability. The data strongly suggests that P4Qs with atropisomeric character possess improved in
vivo antimalarial efficacy in a P. berghei infected mouse model.
Solubility hurdles were also conquered with a prodrug strategy especially when such a
limitation is caused by compounds in which first-pass metabolism is not the main route of the
systemic drug delivery. At the same time, preference is given to prodrugs that can regenerate the
parent compound via chemical methods rather than the ones depending on enzymatic reactions.
We have implemented and examined a prodrug approach, in which the prodrug is highly soluble
and stable at low pH, but decomposes to its parent compound by elevating the pH of the media.
A selected set of pH-triggered prodrugs of 3-aryl-4(1H)-quinolones has been shown to possess
improved in vivo antimalarial efficacy in a P. berghei infected mouse model. More importantly,
the pH-regulated strategy of releasing the parent compound is easily applicable to the other
classes of 4(1H)-quinolone compounds. For instance, several research groups including ours
have focused their resources in developing and 4(1H)-quinolone antimalarials such as 4(1H)pyridones, 1,2,3,4-tetrahydroacridones, 4(1H)-quinolone esters, 2-aryl-4(1H)-quinolones, and 3-
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carboxyl-4(1H)-quinolones which all being limited by the poor solubility. We believe that our
work in the area of alternative routes of enhancing solubility will provide insights and a flexible
strategy to overcome this physicochemical barrier for all 4(1H)-quinolone-based antimalarial
drug candidates.
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